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Chapter I 
INTRODUCTION 
In today's medicine many decisions are based on data from the clinical chemistry 
laboratory. 
Basically laboratory results for a specific constituent serve a dual purpose (35, 65): 
a. to recognize the diseased individual by relating the value found to either the 
range of values observed in a healthy population or to a range of values known 
to be compatible with a specific condition. 
b. to monitor changes in an individual patient. 
Consequently measurements in clinical chemistry have to be reliable in two ways. 
Firstly, they have to be accurate, which is defined (I ,34a) as close to the true value 
or an accepted reference value and secondly, they have to be precise, which means, 
that replicate test results have to agree closely (1,34a). The question that has often 
been discussed but hitherto not been answered satisfactory is: how accurate and 
how precise do measurements in clinical chemistry have to be? 
In general in technical disciplines, requirements for accuracy and precision of measure-
ments are set by the consumer needs. For example in steel construction the conse-
quences of measurement errors are carefully considered. If the length of beams is 
incorrect or shows variations, all or some will not fit. If the actual shapes are smaller 
than designed shapes or if the strength of the material is insufficient the construc-
tion may collapse. If the strength/weight ratio is low the beams will be too expensive 
to meet the budget. Technical and economical consequences of each deviation from 
the ideal or required dimensions can be calculated, and, not unimportant, instru-
ments used for measurements are adequate to register these deviations. 
In clinical chemistry consumer needs are more difficult to define. 
Firstly, ideal or required values are difficult to establish: 
- biological differences between individuals exist and apparent identical physio-
logical conditions occur together with constituent levels which differ from individ-
ual to individual 
we have to deal with physiological variations within the individual patient. The 
constituent level in a person may change due to dietary conditions, diurnal varia-
tions, body position etc., which are without significance for the condition of the 
patient or for the conclusion to be drawn from the measurement 
the clinical chemistry result is only part of a series of observations, made by a 
physician during examination of a patient. In the process of medical decision 
making the degree of importance of the clinical chemical test result as compared 
to other data obtained for the same patient varies from case to case. 
Secondly, clinical chemistry measurements are seldom carried out with impeccable 
accuracy and precision. Routine analytical variability or rather variability in the 
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total process from sample taking to the final analytical result is for many consti-
tuents not negligible as compared to either intra-or interindividual biological varia-
tions or clinically important differences. 
There are a number of chemical, physiological, practical and economical factors 
interfering with the estimation of in vivo levels of blood constituents, e.g.: 
blood serum levels to be measured may change during sample taking and 
clotting due to chemical conversion or exchange with intracellular compart~ 
ments 
the method used for measurement may not be specific and, for example 
overestimate the constituent by measuring related compounds 
the method used may be sensitive to substances interfering with the chemical 
reactions 
the technician may not be familiar with proper handling of technical devices 
or instruments 
the standards and/or reagents used may contain impurities leading to erroneous 
results, instruments may not function properly. 
These factors lead to inaccuracy if their effects are constant from sample to sample, 
from day to day, from technician to technician or from lot to lot of reagent chemi~ 
cals. The same factors will lead to imprecision, if they are variable between samples, 
between days, between technicians or between lots. 
This discussion shows why it is difficult to define how accurate and how precise 
clinical chemistry measurements should be. 
Most attempts to attack the question have been made from the theoretical point of 
view. They are based on the assumption, that the analytical variability should not 
exceed a certain proportion of the human biological variation. 
Tonks (6la,b) states that allowable limits of error should not exceed 1/4 of the 
normal range, corresponding with a ratio of about 2 to 1 of the biological variation 
to analytical variation. Zwart Voorspuij and Van der Slik (77) recommend a ratio 
of "3-5: 1 between physiological variation and analytical variation". Yanko (62) 
reports that the Center of Disease Control (CDC) uses the 4:1 ratio in its proficiency 
programs, this being a compromise between the 3:1 to 5:1 ratio suggested by Barnett 
(4) 
Campbell and Owen (9) and Barnett (4) were the first to deal with the problem 
from the clinical point of view. Campbell and Owen report "acceptable analytical 
limits in the view of a number of clinicians" and Barnett gives tables of "medically 
significant values, synthesized from opinions of clinicians and laboratory specialists". 
More recently Gilbert (27) derived "analytical goals" from Barnett's data. 
Cotlove and coworkers (14), in their hallmark paper on intraindividual variation, 
stressed that tolerable analytical variability should be based on variation within 
the individual rather than on biological variation between individuals or '·on judge-
ment derived from experience with test results that incorporate undetermined 
degrees of analytical variation". Cotlove's approach has recently been used by 
Steele c.s. (58) to arrive at requirements for analytical performance. 
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The !FCC (International Federation of Clinical Chemistry) Expert Panel on Nomen-
clature and Principles of Quality Control in Clinical Chemistry has issued a provisional 
recommendation on "Quality requirements from the point of view of health care" 
(34b) and it is clearly stated that 
"consumer needs - i.e. health care requirements as determined by benefit to patients, 
clinical practice and cost to the community - must be taken into account, in order to 
avoid wrong management decisions which might result from reliance on internal laboratory 
criteria alone; for example, an analytical method may be the best available for a given 
component, but it may still be not good enough for clinical application; conversely, a 
method may be more sensitive, specific or costly than justifiable by its use in a particular 
clinical situation". 
We conclude that a close interaction between laboratory and clinician in the field 
of quality control is indicated to arrive at sensible requirements for analytical reliabil-
ity. 
The difficulties to be encountered in setting these requirements from the clinical 
point of view are related to (a) the inherent analytical variability of various determi-
nations and (b) the well documented differences among physicians in criteria used in 
medical decision making (7, 11, 16. 22, 53, 64, 74). Elsom and coworkers (22) 
report on the "extraordinary independence of objective data displayed by more than 
300 physicians in arriving at a diagnosis" and Clark et. a!. (11) notes: "It is impossible 
to determine how an examiner arrived at a diagnosis and how he interpreted laboraN 
tory reports". This may well be a too pessimistic picture of the situation since for 
example, none of these studies took into account the effect analytical variability may 
have on the recorded differences in clinicians' behaviour towards laboratory results. 
The aim of the study described in this report was to get an hnpression of the present 
situation: how do physicians use laboratory results and does analytical variability 
affect medical decision making. In particular we tried to get an answer to the ques-
tion for which determinations analytical performance is - from the clinical point of 
view - good, adequate or elegible for improvement respectively. 
A questionnaire was designed dealing with various aspects of medical decision making. 
Specialists in internal medicine in different hospitals were interviewed in person, 
while simultaneously relevant data from the hospital laboratory were collected. 
In this report the following subjects will be discussed: 
normal range 1 ) values given by the laboratory will be related to those applied by 
physicians and to '·action levels" given by them. Action level is defined as the 
upper or lower limit of a constituent level that would prompt to an action of 
the first order (repeat or additional tests, E.C.G, X-ray, change of diet or medica-
tion) in the specific situation of the out-patient with ill-defined complaints. The 
occurance of systematic differences between laboratories can be considered at 
1 ) It has been suggested {18,31) that the term "reference values" or "reference interval" should 
be used instead of .. normal range", for the range of values, observed in healthy individuals. 
The author prefers the latter term at present, for reasons which will be given in chapter Ill. 
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the same time, since all laboratories tested samples of the same quality control 
sera 1 ) multiple times. 
The difference between limit of normal and respective action level will be con-
sidered a measure of the strictness the physician applies at that concentration 
level for that constituent. 
a medically significant change in an individual patient will be related to analytical 
variability observed in this study 
in addition clinicians' views on the following points will be reported: 
a. factors affecting variation in results (physiological variation, laboratory error, 
sample handling) 
b. satisfaction/dissatisfaction with laboratory performance 
c. request of repeat tests and consulting the laboratory in case of an unlikely 
result 
d. the speed of availability of an analytical result versus its reliability. 
e. the use of molecular units in medical practice 
f. interpretation of results of another laboratory. 
1 ) Quality control sera are large pools of serum, subdivided into small portions and stored 
either frozen or in lyophilized form so to guarantee a minimum change in concentration of 
the constituents over a stated period of time. 
For Hb analyses special liquid quality control samples were used. 
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Chapter II 
DESIGN OF THE PROJECT AND PROCEDURE 
2.1 Design of the project 
2.1.1 The inquiry 
A questionnaire was set up in cooperation with the departments of psychology 
(Prof. Dr. F. Verhage) and biostatistics (Dr. R. van Strik) of the Erasmus University. 
After a pilot study including interviews with 4 clinicians minor changes were made 
in the questionnaire. 
Specialists in internal medicine were considered to be - quantitatively and qualita-
tively - the most demanding clinicians with respect to laboratory tests. A selection 
was made of senior internists in University hospitals or teaching hospitals affiliated 
with University hospitals. In the Netherlands there are 30 hospitals with postgraduate 
training courses in internal medicine ("Interne A opleiding"). The interviewer had 
the opportunity to interview ten clinicians in three hospitals outside the Netherlands. 
The following table gives the interviewers by hospital: 
type of hospital country number of hospitals number of clinicians 
interviewed 
University hospital Netherlands 4 33 
., Switzerland I 3 
United States I 4 
Canada I 3 
Teaching hospital Netherlands 5 20 
12 63 
In the university hospitals in the Netherlands 8 or 9 randomly choosen associate 
professors and "chefs de clinique" were interviewed. In teaching hospitals all senior 
specialists in internal medicine working in that hospital were questioned. Four out of 
67 clinicians turned down the request for participation. 
The age distribution of the participants is given in the following table: 
years after MD degree: 0-5 5-10 10-!5 15-20 20-25 25-30 30-35 
number of clinicians: l i4 16 14 7 5 2 
2 .I .2 The survey 
The laboratory survey was set up as follows. 
Each laboratory tested 20 vials, 10 of a normal and !0 of a pathological quality 
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control serum in pairs on separate days over a period of 2-5 weeks. The analyses 
under study were among the most commonly requested tests: sodium (Na), potassium 
(K), chloride (Cl), calcium (Ca), inorganic phosphorous (P), urea, creatinine (creal.), 
glucose (glue.), cholesterol (chol.), total protein (t. prot.), alkaline phosphatase (alk. 
P-ase, ALP) and lactate dehydrogenase (LDH). 
Also 20 vials of hemoglobin (Hb) control material, 10 at each of two levels, were 
tested. 
The lyophilized control sera formed part of the normal and abnormal pools (1974) 
of the Massachusetts Society of Pathologists regional Quality Control Program (12). 
Due to an error one laboratory tested samples of the 1975 pools. 
No target values for the quality control sera were known to participants. The Hb 
controls had assigned values printed on package and vial by the manufacturer. 
For the ten results for each controlmaterial mean, standard deviation (SD) and 
coefficient of variation (CV) were calculated. Figure 2-l gives an example of the 
form used for reporting the results of the survey to laboratory directors: laboratory 
identification number, constituent tested, mean, SD and CV are listed. In a two-
sample plot the individual values and mean value are accumulated. In addendum I 
it is demonstrated how this cumulative two-sample plot - a modification of the two-
sample plot introduced by Skendzel and Youden (51) and Tonks (6la)- can provide 
valuable information on intra- and interlaboratory variability. 
Laboratory directors filled out a questionnaire on normal values: 
Nor mal values 
Units 
Are the normal values* 
- derived from the literature 
or instrument or kit manual 
~ determined in your laboratory 
- an estimate 
Na K Cl Ca p urea etc. 
If normal values were determined in your laboratory, please answer the following questions: 
When were they determined* 
~ less than 1 year ago 
~ between 1 and 3 years ago 
~ more than 3 years ago 
Number of persons 9 
d 
Age range 9 
Population* 
- blooddonors 
students 
- hospital personel 
- out-patients 
other 
d 
*: please place x at correct answer 
~,So 
2,6o 
2,-ro 
Figure 2-1: 
lab.nr. Q'f 
<:onatlh.Janl Ca.. 
month 
Nl"um X-1 
-· IH~I so cv 
Hrum X-II 
-· liiii so cv 
M: -of all lab!; 
-2-: 2 SO Hmilt e~ll lab.; 
R : .._,of ref. labs. 
' 
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I I I J I I I D 
I I I I I !±±:J 
"x" doily resuiB your lob. 
"X" mean your lab. 
213o 
Example of form used for reporting survey results to laboratory directors. Explanation of symbols 
used in the two-sample plot: 
M : mean of all laboratories' mean values in the Massachusetts Regional Quality Control 
Program 
-2- : 2 SD limits of all laboratories' mean values in that program 
x : individual results laboratory 4. 
X : mean value laboratory 4. 
Details of this way of reporting are given in the addendum I. 
2.2 Procedure 
First, an appointment was made by telephone with the director of the hospital 
laboratory. In a 1-2 hour meeting the organizational plan of the project was explained 
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and cooperation was asked with the survey. It was made clear that the project would 
be anonymous, i.e. that no information from the laboratory would be reported to 
cli_nicians nor vice versa. 
Next, the following letter was written to the clinicians to be interviewed: 
Dear Doctor, 
I would like to invite your attention for an inquiry, that has been set up by me in the 
course of my doctorate studies. 
It is the aim of this project to get an impression of the way the clinician uses laboratory 
results in clinical diagnosis and the follow·up of patients. 
In consultation with Prof. Dr. B. Leijnse, department of Chemical Pathology, Erasmus 
University, Rotterdam a questionnaire has been composed, that will be submitted to ·a 
number of medical specialists. 
I would like to ask for your cooperation with this project by answering the questions in 
person. Next week I will contact you by telephone and on that occasion I would like to 
make an appointment for an interview, that will take about 35 minutes. 
Your cooperation will be greatly appreciated. 
After a week an appointment was made by telephone. The appointments with the 
clinicians in Switzerland, the United States and Canada were in part made through 
the laboratory director. 
The interviews lasted 2540 minutes, eleven exceeded 40 minutes. 
If lack of time was impending question lc of the questionnaire (seep. 15) on consti-
tuent levels prompting to an action of the second order (hospital admission, imme-
diate treaiment) and the details on desired degree of precision asked in question IVb 
and Vlb were left out. 
The introduction to the interview and the questionnaire read as follows: 
"In clinical chemistry much attention has been paid to quality control over the last years. At· 
tempts are being made to improve day·to·day reproducibility in the laboratory and comparabil· 
ity between laboratories. 
One question actually has remained unanswered: which accuracy and precision are required from 
the laboratory to render good service to the clinician? In the clinical chemistry world an answer 
to this question has been looked for and it has been proposed, that analytical variability should 
not exceed "% of the biological variability. If that criterium is met, one should be able - from the 
statistical point of view - to distinguish the diseased individual from the healthy population. 
This is a theoretical approach; when we extrapolate this line of reasoning to the - often small -
biological variation within one individual, which is frequently a matter of concern in the practical 
situation, we arrive at a requirement for example for Na, that reproducibility should be better 
than !4% (l_CV). Then the question arises, how many physicians would appreciate this precision. 
Of course there is also an economical side to the problem. 
It is difficult to ask the clinician how accurate and how precise the laboratory should be. His 
impressions are based on the accuracy he gets from his laboratory. Yet it does seem pertinent to 
analyse the present situation: when does a clinician react to an abnormal laboratory result, 
when does he consider a change in a patient medically significant. The tests we will discuss in 
the fust instance are some of the most commonly requested: Na, K, Cl, Ca, P, urea, creatinine, 
glucose, cholesterol, total protein, Aile P'"<ise, LDH and Hb. 
Simultaneously we get information from your laboratory on these tests, but no information will 
be exchanged. 
Their data will not be passed on to you, nor will any of your information be relayed to them. 
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Ia. Which normal values do you apply? Na, K, Cl, Ca etc. 
If you apply different normal values for men and women or for people in different age 
groups, please identify. 
b. Are the values mentioned under a.: 
derived from the literature? yes/no 
if so, from which textbook or publication? 
concluded from own personal observation? yes/no 
based on the normal values given by the laboratory? yes/no 
other 
c. Suppose you find no abnormalities during a physical examination of a patient with ill~ 
def'med complaints. You order a number of laboratory tests. 
Please identify for each constituent a lower and an upper limit which would prompt you 
to action of the fust or second order. An action of the first order (Action 1) does include: 
repeated or additional laboratory tests, ECG, X-ray, initiation or change of diet or medica-
tion. An action of the second order (Action II) is defined as: hospital admission, immediate 
treatment. Na, K, Cl, Ca etc. 
II Suppose you find in a patient under your treatment the laboratory result given in the 
table. You follow the course of this patient and/or the effect of treatment. Pleace circle 
the value, that would represent a significant change - in these cases improvement -
(See section 5.1 for details). Na, K, Cl, Ca, etc. 
III There are a number of factors responsible for the day-to-day variability of laboratory 
data. We have the biological variation in the patient, laboratory error, handling of the 
sample (e.g. technique of sample taking or storage) and possibly other factors. Can you 
indicate to which extent these factors contribute to this variability: very great:++, great: +, 
moderate:± or none-. 
biological variation in the patient ++/+/±/-
laboratory error ++/+/±/-
handling of the sample ++/+/±/-
other ++/+/±/-
IVa For which constituents do you feel a greater accuracy of the laboratory is needed: in other 
words, are there laboratory tests for which you would say: I could do better work, if the 
laboratory did a better job'? 
b Please identify the degree of accuracy desired (Sate two values, between which you want 
to distinguish). 
Va Do you ever order a repeat test - on a new sample - before making a medical decision 
always/often/ sometimes/ never 
b Suppose the value reported for a repeat test is substantially different from the first time. 
How do you proceed'? 
you order the test for a third time always/often/sometimes/never 
you consult with your laboratory always/often/sometimes/never 
you disregard the value that is least likely in the given situation 
a1 ways/often/ sometimes/ never 
VI Are there blood constituents - possibly others than the ones named in the table - for 
which you would prefer a fast semiquantitative result (within an hour) over an accurate 
value on longer terms. Please state the degree of accuracy desired (two values between 
which a distinction is to be made. 
VII Suppose a patient is referred to you, while laboratory tests data have been determined 
in another laboratory than your own. How do you proceed'? 
you evaluate the results with the normal values 
you usually apply in mind yes/no 
you ask for a repeat of all tests yes/no 
you ask for a repeat of clinically relevant tests only yes/no 
you relate the data to the normal values of the laboratory in question yes/no 
if these normal values are not directly available, do you inquire'? yes/no 
VIlla Suppose a patient is referred to you from another hospital. In the table the laboratory 
value reported for this patient is given. You ask for a reueat test in your own laboratory 
and fmd the other value given in the table (see section 7 .1). Na, K, Cl, Ca etc. 
Is there a change in the condition of the patient'? yes/no 
!6 
b What would be your answer if the two values were results for one patient both determined 
in your own laboratory. 
IXa a. Does your laboratory report in molecular units'? yes/no 
b. If so, since when? 1970/1971/1972/1973/1974/1975 
c. How long did it take you to get used to the new units? 
<3 months/3-12 months/> 1 year 
d. Have molecular units enabled you to give better treatment to patients? 
yes/somewhat/no 
e. Have molecular units given you more insight into biochemical processes? 
yes/somewhat/no 
f. Do you convert mmol/1 into mg% before making a medical decision? 
always/ often/ sometimes/ never 
g. Do you convert mg% e.g. from the literature into mmol/1 for optimal interpretation? 
always/ often/ sometimes/ never 
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Chapter lil 
THE LABORATORY SURVEY AND THE INQUIRY INTO THE LABORATORIES' 
NORMAL RANGE VALVES 
3 .I Introduction 
In order to collect information on intra- and interlaboratory variability of analyses 
each laboratory tested quality control materials at two different levels on ten differ-
ent days. Laboratory directors gave information on normal range levels applied in 
their laboratories. Details of the survey and inquiry are given in chapter II. 
3.2 Results 
3.2.1 The survey 
In table 3-1 the average results (X) found by each laboratory (numbered I through 
12) for quality control (q.c.) material I and II, the standard deviation (SD) and the 
coefficient of variation (CV) of the ten determinations are listed. At the bottom of 
each table the mean (M), SD and CV of the average results of all laboratories are 
given. In addition median intralaboratory SD and CV are listed. 
In figure 3-3 the average result for quality control material I and I! for laboratories 
1-12 are given in histograms. If the standard error of the mean (SE) exceeded half 
the width of the class interval a horizontal line represents the SE. For example for 
sodium, the scale is graduated: 121, 122, 123 mmol/1 etc., the width of the class 
interval thus representing a variation of± 0.5 mmol/1. Only SE's larger than 0.5 
mmol/1 are indicated by horizontal lines. 
The upper and lower limits of .the normal range reponed by laboratory directors 
are given in the same graph below the concentration scale. 
We concluded systematic analytical bias to exist, if for a certain constituent the 
average result reported by a laboratory ranked high or low for both controlsera in 
relation to the group. Therefor we ranked laboratories according to their average 
results for both controlmaterials from I to 12 and then added the two rank numbers. 
The probability distribution of rank sums ranges from 2 to 24, a rank sum of 13 
being most likely to occur. The cases where rank sums exceeded 21 or were lower 
than 5 are listed in table 3-4. This technique has been described by Youden (72). 
In the same table an indication is given whether or not systematic analytical bias is 
reflected in the range of normal values. In cases where normal ranges were derived 
from the literature this is mentioned. Systematic analytical bias was considered to 
be reflected in the range of normal values when rank sums for the lower and upper 
limit of normal exceeded 18 or were lower th:in 8 simultaneously with high or low 
systematic bias respectively. 
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S 0 D I U M POTASSIUM 
control I control II control I control II 
LAB x, SD cv XII SD cv LAB x, SD cv XII SD cv nr nr 
I 140 2,0 1,4 120 I ,5 I ,3 I 5,6 0, II I, 9 3,3 0,06 2,0 
2 140 I ,3 0,9 118 1,4 1,1 2 5,8 0,05 0,8 3,4 0, ll 3,2 
3' I ,4 1,0 I ,6 I ,3 3' 5,8 0,08 I ,4 3,3 0,07 2,0 
4 144 I ,3 0,9 123 1,1 0,9 4 6,0 0,07 I ,2 3,4 0,05 I ,3 
5 141 I ,3 0,9 120 I ,5 I, 2 5 5,8 0,13 2,3 3,4 0,07 2, I 
6 140 I ,5 1,1 119 1,0 0,8 6 5,6 0, 12 2, I 3,3 0, 12 3, 7 
7 138 I ,6 I, 2 118 I ,8 I ,5 7 5,8 0,05 0,9 3,3 0,08 2,4 
8 140 0,7 0,5 120 2,5 2, I 8 5,7 0,05 0,8 3,3 0,08 2,3 
9 141 0,9 0,6 120 I, 5 I, 2 9 5,9 0, II I, 9 3,4 0,06 I ,8 
10 143 I ,4 1,0 121 0, 9 0, 7 10 5,9 0,07 1,2 3,4 0, 07 2,0 
II 141 0,5 0,3 121 I ,0 0,8 II 5,9 0,03 0,5 3,3 0,04 1,1 
12 141 0,8 0,6 120 I, 3 I ,0 12 5,8 0,05 0,8 3,4 0,05 1,5 
M 140,8 I ,3 0,9 120,0 I ,5 1,2 M 5,80 0,07 I ,2 3,35 0,07 2,0 
<d I ,6 I ,4 <d 0,12 0,05 
cv I, 13% 1' 17% cv 2,06% I ,52% 
C H L 0 R I D E c A L c I U M 
control I control II control I control II 
LAB x, so CV XII SD cv LAB x, SD cv XII SD CV nr nr 
I 114 I ,6 1,4 99 1,3 I, 3 I 2, IS 0,05- 2,5 2,65 0,08 2, 9 
2 115 2,3 2,0 100 1,4 I ,4 2 2,26 0,04 I, 6 2,82 0,03 I ,0 
3' 117 I, 7 I ,5 102 I, 2 I, 2 3' 0,03 I, 2 0,07 2,8 
4 118 I ,0 0,8 102 I, 7 I, 7 4 2,08 0,05 2,4 2,65 0,06 2,2 
5 115 2,3 2,0 99 I ,9 I ,9 5 2,21 0,06 2,5 2,69 0,11 4,0 
6 114 2, I I ,8 99 I ,8 I ,8 6a 2,20 0,06 2,6 2,64 0,06 2, I 
7 118 0,5 0,4 I 00 0, 7 0,7 7 2,20 0,02 0,9 2,68 0,03 I ,0 
8 115 I ,2 I, 0 100 2,0 I ,9 8 2,18 0,05 2,2 2,73 0,07 2, 7 
9 114 I, 6 I ,4 100 1,3 I ,3 9 2, 12 0,03 I ,3 2,65 0,03 I ,2 
10 117 I ,3 1,1 100 0, 7 0,7 10 2,28 0,03 I ,3 2,80 0,03 1,0 
II 114 2,2 I ,9 98 2,4 2,4 II 2,09 0,04 I ,9 2,63 0,04 I ,5 
12 114 I ,5 I ,3 98 I ,0 1,0 12 2, IS 0,04 I, 7 2,67 0,03 I ,3 
M 115,4 I, 6 I ,4 99,8 I ,4 I ,4 M z, 1 is 0,04 I ,8 2,692 o,os I ,8 
<d I, 6 I ,3 <d 0,064 0,065 
cv I ,39% I ,28% cv 2,95% 2,40% 
INORG. p H 0 S P H 0 R 0 U s ~ 
control I control II control I control II 
LAB x, SD cv XII SD cv LAB x, so cv XII so CV nr nr 
I, 16 0,10 8,3 2,39 0,09 3,8 7,80 0,34 4,4 21,3 0,60 2,8 
2 I ,24 0,07 5,4 2,59 0,06 3,0 2 7,30 0,64 8' 7 20,9 0,75 3,6 
3' 0,05 3,7 0,09 3, I 3 c 7, 20 0,23 3,2 20,6 0,31 I ,5 
4 I, 19 0,03 2,6 2,54 0,06 2,4 4 7, 64 0,24 3, I 21,0 0,52 2,5 
5 I, 15 0,03 2,4 2,49 0,14 5,6 5 7,28 0,20 2,7 20,9 0,86 4, I 
6a 1' 16 0,05 4,4 2,49 0,06 2,3 6 a 6, 70 0,36 5,4 21,2 0,88 4,2 
7 I, 1 7 0,02 I, 5 2,55 0,05 I ,8 7 7 ,37 0,08 1,1 22, I 0,41 I ,9 
8 I, 17 0,02 2,0 2,43 0,04 I ,5 8 7,24 0,13 I ,8 20,9 0,57 2' 7 
9 1,16 0,06 5,0 2, !3 0,09 4,3 9 7,33 0,19 2,6 20,9 0,19 0,9 
10 1 '16 0,03 2,3 2,54 0,06 2,3 10 7,25 0,18 2,5 20,3 0, 7 0 3,3 
II I, 14 0,04 3, I 2,51 0,05 1,8 II 5,66 0,21 3,8 18,4 1,5 0 7,9 
12 I, 14 0,03 2, 6 2,48 0,08 3,0 12 6,95 0,21 3,0 20,8 0,36 I, 7 
M 1' 16 7 0,04 2,9 2,467 0,06 2, 7 M 7' 143 0,21 3, I 20,78 0,59 2,8 
<d 0,028 0, 125 <d 0,545 0,86 
cv 2,39% 5,07% cv 7,62% 4,15% 
Table 3-1 
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C R EAT I N I N E G L U C 0 S E 
control I control II control I control II 
LAB XI SD cv XII SO cv LAB XI so CV XII SO cv nr nr 
166 7' 1 4,3 450 15,3 3,4 I 5,60 0,36 6,4 II ,6 0,57 4,9 
2 ISS 4,4 3,0 449 9, 7 2, I 2 5,20 0,20 3,8 12,1 0,27 2,3 
3' 148 5,2 3,4 443 5,3 I, 2 3' 5,80 0,13 2,2 13,3 0,33 2,5 
4 152 4,8 3,2 437 9,9 2,3 4 4,93 0,16 3,2 10,3 0,49 4,8 
5 166 4,5 2,8 479 26,2 5,5 5 5,63 0,29 5,2 ]] ,9 0,59 5,0 
,. 170 7,8 4,6 460 I 0, 2 2,2 sa 4,49 0,32 7, I 11,2 0, 70 6,3 
7 162 2,0 I, 2 471 17,3 3,6 7 5,36 0,33 6, I II ,8 0, 70 5,9 
8 159 2,8 I, 7 464 7, I I ,5 8 5,78 0,27 4,7 12,4 0,33 2,6 
168 I I, 9 7, I 433 12,6 2,9 9 4,80 0,16 3,3 II, 3 0,40 3,5 
10 153 3,2 2, I 442 11,1 2,5 10 5,05 0,29 5,8 11,1 0,40 3,5 
II 151 3,6 2,4 467 24,0 5, I II 6,09 0,26 4,3 12,3 0,68 5,5 
12 152 7, 5 4,9 473 35 7, 4 12 6, 28 0,33 5,3 13,3 0,64 4,8 
M 158,5 4,7 3, I 455,7 II, 9 2, 7 M 5,418 0,28 5,0 11,88 0,53 4,8 
ad 7,6 15,3 ad 0,541 0,88 
cv 4,81% 3,36% cv 9,98% 73,9% 
C H 0 L E S T E R 0 L T 0 T A L p R 0 T E I N 
control I control II control I control II 
LAB XI so cv XII SO cv LAB XI SO cv XII SO CV nr nr 
I 4,08 0,21 5, I 3,69 0,20 5,3 66,6 2,6 4,0 57,0 J.' 3 7, 2 
2 3,37 0,14 4, I 2 67,6 I, 7 2,5 57,5 I ,5 2,6 
3' 0, 12 3,5 3' I ,8 2,8 0, 9 I ,6 
4 4,27 0, 17 4,0 3, 91 0, I 3 3,3 4 67,9 I ,4 2, I 56,5 I ,0 I ,8 
5 4,07 0,13 3, 2 3,93 0, 19 4,8 5 64,2 2,8 4,3 55,1 2,3 4,2 
sa 3,70 0, !8 4,8 3,28 ,. 66,6 I ,8 2,7 53,4 I ,5 2, 7 
7 4, I 6 0,08 I, 9 3,93 0,08 2,0 7 65,8 0,6 0,9 54,8 0,8 I ,4 
8 4,31 0,13 3,0 3,93 0,14 3,6 8 68,9 I ,0 I ,5 57,5 I ,2 2, I 
9 4, 16 0, 19 4,6 3,85 0,11 2,9 9 67,2 0,6 0,9 56,0 I ,3 2,3 
10 4,39 0,07 I, 7 4,25 0, 21 4,9 10 66,8 0,8 I, 2 54,9 I ,0 I ,8 
II 4,32 0, 13 3, I ~.os 0, 15 3,8 II 66,1 I, 7 2,6 57,5 0, 7 I ,3 
12 4,25 D,ll 2,6 4,05 0,23 5, 7 12 68, I 1,0 I ,5 58,5 I ,8 3,0 
M 4,098 -o, 13 3,4 3,887 0,15 3,8 M 67,00 I, 6 2,3 56,20 I ,3 2,3 
>d 0,305 0,258 ad I ,30 1,.54 
cv 7,43% 6, 64% cv I, 94% 2,74% 
A L K. P H 0 S P HATA S E L 0 H 
control I control II control I control II 
LAB XI SO cv XII so cv nr LAB x, SO nr cv XII SD cv 
I 52 I, 7 3,2 163 6,2 3,8 I 100 7, 6 7,6 383 22 5,8 
2 92 6,5 7, I 316 14 4,4 2 80 7,3 9, I 286 26 9,2 
3' 3, I 3,3 3' 3, I I ,6 
4 89 4,6 5,2 274 14 5,0 4 153 14,4 9,4 605 24 3,9 
5 84 12 14,4 322 40 12,5 5 140 17 12 565 70 12,4 
6 65 4,3 6,6 191 8,4 4,4 6 113 6,5 406 18 4,5 
7 46 5,5 12 145 16 II )b 3,4 4,6 
8 31 I ,4 4,5 97 2, 7 2,8 8 211 17 7,9 )59 36 4, 7 
9 40 2,0 5,0 122 4,8 3,9 9 166 II 6,3 520 22 4,3 
10 87 4,3 5,0 280 3,3 I, 2 10 151 7,5 5,0 591 25 4,2 
II 96 3,9 4, I 326 II 3,3 II 126 3,8 3,0 475 22 4,6 
12 76 4, 7 6,2 250 13 5,2 12 156 12 7, 6 592 25 4,3 
M 5, I 4 2 M 7, I 4,6 
>d ad 
cv cv 
Table 3-1 cont. 
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HEM 0 G L 0 B I N 
control I control II 
LAB x:, SD cv XII SD CV nr 
lb 
2 5, 17 0, 19 3,6 6,87 0, 18 2,6 
3 5,27 0, 10 I, 9 6,74 0,12 I ,8 
4 5,30 0,07 I ,3 6, 77 0,07 I ,0 
5 5,38 0,20 3, 7 6,84 0,25 3,7 
6 
7b 
5,15 0,12 2,2 6, 77 0, 09 I ,3 
8 5,23 0,07 I, 2 6, 71 0, 13 I, 9 
9 5, 18 0,09 I ,8 6,55 0,14 2, I 
10 5,34 0, II 2,0% 6,'74 O, I! I ,6 
II 5,41 0,09 I, 7 6,87 0,16 2,3 
12 5,47 0, 07 I, 2 6,98 0,06 0,9 
M 5,290 0, I 0 I, 9 6,784 0,13 I, 9 
>d 0,109 0,116 
ov 2,06% I, 7% 
Table 3~1. 
For each constituent and for each hospital laboratory, numbered 1 through 12, the average value 
(X) of 10 results for the q.c. materials I and II and their dispersion, expressed as SD and CV are 
presented. At the bottom of each table the mean, SD and CV of the average values of all labora-
tories are given. In addition median SD and median CV of intralaboratory variability are listed. 
Mean of averages and median SD are denoted by M. For the enzymes Alk. P-ase and LDH no sum-
marized data are given for reasons of methodological differences, except for the median CV. 
Footnotes: 
a. In laboratory 6 two types of methodology are available for a number of constituents. 
Screening by means of a SMA 12/60 is performed on out-patients samples and special 
methods are applied to samples of in-patients. This laboratory tested the controlmaterials 
5 times on the SMA and 5 times with the other methods. The interviewer had admittance 
to quality control records of this laboratory. In table 3-1 the average values for the SMA are 
given, since possible systematic analytical bias between laboratories is - in chapter IV -
related to physicians answers on action levels in the out-patient situation. The intralabora-
tory variabilities are given for the special methods since these data will be used with the 
interpretation of physicians' answers to the question: "what do you consider a significant 
change within a patient", which relates to the in-patient situation (chapter V). 
b. Laboratory 1 did not test Hb controls, since they were not available at the time. Results 
for Hb controls of laboratory 7 were lost. For this laboratory no mean value for LDH was 
obtained. Intralaboratory variability (CV) is given for 1975 pools. 
c. Due to a mistake laboratory 3 tested the 1975 pools of the Massachusetts quality control-
sera. The structure and the targetvalues of these materials do not differ much from the 1974 
pools and intralaboratory variability was entered as such (CV). Information for both the 
1974 and the 1975 pools was available for one reference laboratory and these were com-
pared to those of laboratory 3. For some constituents a proportional or absolute systematic 
difference with the reference laboratory was evident and corrected results are entered in the 
table for laboratory 3. For example for potassium: 
ref. lab. 
lab. 3 
!975 
serum I 
5.81 mmol/1 
5.74 mmol/l 
serum II 
3.64 mmol/I 
3.56 mmol/l 
serum I 
5.83 mmol/1 
5. 76*mmol/l 
!974 
serwn II 
3.40 mmol/1 
3.32*mmol/l 
For K, Cl and creatinine a constant systematic difference was observed and brought into 
account, for urea and glucose a proportional systematic difference. 
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In table 3-10 lntralaboratory variability observed ln this survey (median and range) 
are given together with those of the Quality Assurance Service of the College of 
American Pathologists (38,48) as a comparison. 
3.2 .2 The inquiry 
In table 3-2 the laboratory directors' answers to the inquiry on normal range values 
are given. In figure 3-3 the upper and lower limits of normal reported by the labora-
tory are presented in histograms below the concentration scale while average results 
for both quality control materials are plotted above this scale. 
3.3 Discussion 
The data presented in this chapter on dispersion of analytical results withln each 
laboratory and between laboratories as well as the data on the laboratory's normal 
range values will be considered in the next chapters in relation to physicians' views 
on medical significance. In tills regard we will be particularly interested in the follow-
ing points: 
- is there systematic analytical bias between laboratories? Can observed differences 
in normal range values be explained by systematic bias? 
- whlch other factors can be responsible for observed differences in normal range 
values? What is the relevance for this study? 
what is the median intralaboratory variability and is there a significant difference 
between laboratories as to intralaboratory variability? 
3.3.1 Systematic bias between laboratories and differences in normal 
range values. 
If we are to draw conclusions from the survey data as to the existence of systematic 
analytical bias between laboratories we have to keep ln mind, that the survey, although 
it covered 2-5 weeks of testing, gives a picture of short -term bias. To keep a labora-
tory determination consistent over long periods of time is difficult ( 19 ,26). Al-
though the differences in mean values for survey results are statistically significant 
(fig. 3-3) in many cases, we did not subject the survey results to extensive statistical 
analysis and have considered the most evident cases only in combination with the 
data on normal range values given by the laboratory directors. 
To this purpose in figure 3-3 the frequency distributions of the average results for 
the controlsamples are given together with the lower and upper limit of normal as 
given by the laboratory director. 
From table 34 we see, that in about one-half of the cases where systematic analytical 
bias as compared to the group is present according to the described ranking tests, the 
normal range does not reflect this bias. This is in fact a disturbing situation since the 
normal range is often used as a point of reference between laboratories. It is for 
example common practice in the medical literature to list normal values with case 
histories (31) so to allow the reader optimal interpretation. 
Lab nr 
const. 
Na 
mmol/1 
K 
mmol/1 
Cl 
mmol/1 
Ca 
mmol/1 
p 
mmol/1 
urea 
mmol/1 
ere at. 
umol/1 
glue. 
mmol/1 
chol. 
mmol/1 
t.prot. 
g/l 
ALP 
U/I 
LDH 
U/I 
Hb 
mmol/1 
135-148 
BD/HP, 1-3 
200 
3, 15-4.45 
• 
98-106 
BD/HP/0 >3 
100 
2,38-2.73 
litt. 
0.84-1.35 
litt. 
2.9-8.5 
BD/HP, 1-3 
200 
50-115 
>3 
4.3-6.1 
BD/HP, 1-3 
200 
3.4-7.3 
>3 
62-79 
BD/HP, 1-3 
200 
12-47 
• 
96-240 
>3 
2 
135-148 
HP <1 
20 20-30 
3,5-5.0 
• 
95-107 
• 
2,25-2.75 
• 
0.81-1.65 
• 
I. 8-8.6 
• 
45-115 
• 
3.4-6.2 
• 
3.4-6.5 
• 
61-80 
~ 
11-86 
• 
80-120 
• 
8. 7-11.2 
7.4- 9.3 
• 
22 
3 
135-145 
HP >3 
3,5-5.0 
• 
98-108 
• 
2,20-2.60 
St/HP 1-3 
0.81-1.45 
HP >3 
2.9-7.5 
• 
80-115 
HP <1 
4.2-6.4 
HP >3 
3.4-6.8 
OP >3 
62-78 
HP >3 
20-90 
BD/OP <! 
90-190 
• 
B. 7-11.2 
7.4-10.0 
<1 
4 
135-147 
OP <3 
1500 
3, 1-5. I 
• 
96-108 
• 
2,20-2.70 
• 
0.65-1.30 
• 
3.0-6.7 
• 
50-105 
• 
3.3-5.5 
• 
4.5-7.5 
litt. 
59-83 
BD 1-3 
25-100 
• 
-200 
• 
8.4-11.2 
7.2-10.2 
litt. 
5 
136-147 
HP >3 
40 20-35 
4,0-5.0 
• 
99-108 
• 
2,20-2.60 
• 
1.00-1.60 
• 
3.0-7.5 
• 
50-120 
• 
4.5-6.0 
• 
4.0-7.3 
• 
62-78 
• 
50-135 
• 
-240 
• 
8.5-10.7 
7.3- 9.5 
• 
6 
136-144 
BD/HP, 1-3 
I 00 >20 
4,0-4.8 
• 
96-107 
• 
2,25-2.65 
• 
0.8!-1.45 
• 
2.5-7.5 
• 
70-133 
• 
3.5-5.5 
• 
3.9-7.3 
• 
60-80 
• 
15-60 
• 
-160 
• 
7.5-11.0 
• 
X Determined on the same population sample as for the forgoing constituent. 
Table 3-2: 
Normal range values as reported by laboratory directors. These values were either derived 
the literature (!itt.) or determined in the laboratory, for example: 
"HP<l 
from 
20 20-30" means: normal values were determined on hospital personel, less than 1 year 
ago, number of individuals: 20, age range 20-30. 
Other abbreviations: BD: blood donors, OP: out-patients, ST: students, o: others. 
1) normal ranges were determined on a population sample as indicated. The figures given in the 
table have been corrected taking into account the inhomogeneity of the population sample. 
2) laboratories 8 and 9 collaborated in a project to establish normal range values. 
23 
Lab n<. 
const. 7 8 ') 9 Z) 10 II 1) 12 
Na 135-145 136-148 136-147 !35-145 138-144 136-146 
mmol/1 BD/HP >3 BD 1-3 BD 1-3 HP <I BD <I >3 
100 <65 IOD 18-65 900 20-65 100 20-65 90&10~ 18-65 
K 3. 7-5.0 3.6-5.1 3.6-5.1 3.5-5.0 3.9-5.0 4.0-5.0 
=ol/1 ,. • 
,. 
• 
,. 
• 
Cl 96-106 97-109 97-109 96-108 100-105 95-l 05 
mrnol/1 • • • HP >3 • 30 20-65 
Ca 2. 37-2.79 2.20-2.65 2.20-2.65 2.20-2.60 2.25-2.60 2.25-2.75 
mmol/1 • • • HP <I • litt. 2. 12-2.26 I 00 20-65 
Klin. 
p 0.60-1.40 0.60-1.40 0.60-!.40 0.70-1.45 0 ~ 85-l. 30 0.80-1.30 
mmol/1 
" • • • • 
urea 2.5-6.7 2.5-8.0 2.7-8.2 3.3-7.5 3.0-6.3 3.3-6.7 
mmol/1 
" 
• • • • labjlitt. >3 
creat. 53-106 60-110 55-125 55-110 60-120 -\00 
umol/1 • • <I • • BD 1-3 >3 43~57!1115-60 
glue. 4.0-6.0 3.3-6.0 3.5-5.5 3.1-5.6 3.7-5.6 4.5-6.0 
llllllol/1 • • litt. • BD >3 BD !-3 45d' 5~20-55 100 
chol. 4.0-7.8 3.8-8.6 3.5-8.5 3.9-7.8 4.7-7.8 4.5-7.5 
mmol/1 • • BD 1-3 • BD <I >3 900 20-65 45& 5~18-65 
t.prot. 64-80 65-80 65-80 60-80 65-75 61-76 
g/1 • BD 1-3 • >3 BD <I lab/litt. > 3 100 18-65 90&1 0~1 8-65 
ALP 10-50 I 8-45 15-60 35-130 -100 35-!00 
U/I • • litt HP <I • 100 20.65 
LDH -200 150-350 -160 -200 -175 -200 
U/I • • • • BD >3 40 
Hb 8. 7-J 1.0 8. 7-10.5 7.5-11 .0 8.7-10.6 8.5-10.7 8.7-11.2 
mmol/1 7.4-10.0 7.6- 9.7 8.1- 9.9 7.3- 9.5 7.5-10.0 
• • HP >3 N adults 1-3 BD >3 200 40 2500 . 100 
~etermined on the same population sample as for the forgoing constituent. 
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lab. number of labs. with 
systematic bias in survey results 
high low 
7 
10 
4 
I 
6 
4 
11 
12 
3 
4 
2 
10 
11 
2 
4 
I 
11 
5 
4 
6 
12 
2 
6 
10 
8 
5 
6 
7 
12 
8 
9 
11 
I 
2 
8 
8 
9 
11 
12 
is systematic bias 
reflected in normal range? 
yes 
no 
no 
yes 
no 
no 
no 
yes 
yes 
no 
yes 
no 
no 
no 
no 
yes 
no 
no 
yes 
yes 
yes 
yes 
no 
yes 
yes 
no 
no 
no 
no (litt.) 
yes 
no (litt.) 
no 
no 
yes 
yes 
no 
no (lit!.) 
no 
yes 
Table 3-4: Laboratories where systematic analytical bias for both quality control materials 
towards high or low results is observed are given as well as the answer to the ques-
tion whether or not this bias is reflected in the range of normal values. Criteria are 
given in the text. 
In previous studies we tested the use fullness of the normal range as a point of refer-
ence in interhospital communications in a slightly different way and found it negli-
gible (19, 20). Figure 3-5a represents a graph relating for a group of22laboratories 
in the United States and 22 in the Netherlands the average result of four determina-
tions for a controlserum to the upperlirnit of normal for calcium {20). Figure 3-5b 
gives the same graph for the present study. 
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If systematic analytical bias would be reflected in the range of normal values we 
would expect a correlation between the value of the normal range plotted and the 
result for the controlserum, none is seen. This fmding is in accordance with a report 
ofStn;imme and Eldjarn (59). 
Particularly in enzymology methodological differences cause large discrepancies 
between laboratories and a point of reference is really needed. 
In fig. 3-6 the graph relating control serum result to the upper limit of normal is 
given for LDH, the data being taken from a clinical chemistry survey among dialysis 
and transplant centers in Europe (20) and little correlation is found. Fig. 3-7 gives 
similar graphs for alkaline phosphatase and LDH for the present study. We see better 
results: laboratories reporting a relative low average result for the control serum I in 
general report a relative low upper limit of normal and vice versa. However, we see 
also that in some cases extreme values for the control serum do not go together 
with extreme values for the upper limit of normal as compared to the group. This 
is the case for laboratory II for Aile. P-ase and for laboratory I for LDH. 
This finding is consistent with table 3-4 where systematic analytical bias, taking 
into account the results for both control sera, was found to be reflected in the 
range of normal values in only 3 out of 6 cases of analytical bias for the enzymes. 
Conclusion: apparent systematic analytical bias is not consistently reflected in the 
range of normal values. For the enzymes A!k. P-ase and LDH some correlation is 
seen for the majority of laboratories between the result for control serum I and 
the upper limit of normal (Alk. P-ase: r = 0,8, n = 1 I; LDH: r = 0,7, n = 10). 
3.3.2 Possible causes of differences in normal range values other than 
systematic bias 
There are a number of other reasons why normal range values may differ from 
laboratory to laboratory: e.g. regional population differences, selection of the sample 
of the population for determination of the normal range, intralaboratory variability, 
technique of sample taking, intraindividual variation and dietary, postural or other 
differences in the individuals tested. 
We will discuss these subjects in view of the data laboratory directors provided and 
in view of some recent data from the literature. 
3.3.2.1. Intralaboratory variability 
Flynn et a!. (25) studied the effect of intralaboratory variability on the width of 
the normal range. In table 3-8, column 1 the percentage increase in the range of 
normal values attributable to day to day analytical error is given, with the analytical 
variability of the test in their study. The results of these experiments agree well with 
the mathematically derived data of Gowenlock and Broughton (29) in fig. 3-9. 
Evidently for the electrolytes, particularly for calcium, increased intralaboratory 
variability will increase the width of the range of normal values substantially. This 
subject has also been raised in the medical literature (36,72). 
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Figure 3-Sa: 
Graph relating the average result for calcium, obtained by a group of laboratories for a control-
serum, determined in duplicate on two different days, to the upper limit of the normal range 
reported by the laboratory director. 
(Survey among 22laboratories in New England and 22 in the Netherlands (20)). 
Figure 3-Sb. 
A similar graph, relating average result for controlserum I with upper limit of normal for the 
present survey. 
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serum, determined in duplicate on two different days, to the upper limit of the normal range 
reported by the laboratory director. 
(Survey I among dialysis and transplant centers in Europe (19)). 
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by laboratories 1-12 in the present study, to upper limit of normaL 
However, in our study we see little of this effect. For example for calcium labora-
tories I ,4,5 and 8 who show largerintralaboratory variability than the rest of the group 
do not report wider normal ranges (fig. 3-3). For potassium however, laboratory II 
and 12 show small intralaboratory variability and a relative narrow nonnal range. 
On the other hand, laboratory 6 with the most narrow normal range has the largest 
intralaboratory variability of the group for this constituent. In fact, in 8 out of 
26 cases lowest intralaboratory variability goes together with the widest range of 
normal values or vice versa. Hence, the effect of the intralaboratory variability on 
the width of the normal range could hardly be demonstrated in our study. 
3 .3.2.2. Intraindividua/ variability 
Total intralndividuality day-today variability has been studied most extensively 
by Winkel and Statland (68,69) and Young et al. (75). In table 3-S column 2 and 3 
intraindividual variation in the healthy individual, expressed as coefficient of varia-
tion (CV), has been compiled from their work. Intraindividual variation may increase 
the width of the normal range in the same way analytical variability does and from 
fig_ 3-9 we may conclude that - again - sodium, chloride and calcium will be the 
most sensitive to this influence. 
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t. prot. 
ALP 
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1 
%-age 
increase 
due to 
intralab. 
var. (CV) 
2 3 
intraindiv. 
variab. (CV} 
(68,69) (7>) 
c2o1 
18% (0.6) 0.7% 
8% (1.9) 4.3% 
17%(1.0) 2.1% 
29% (2.6) 1. 7% 
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4 
age/ 
sex 
X 
X 
X 
young 
6>0 
young 
6>0 
aget 
6>0 
X 
age t 
young 
6>0 
age t 
young 
6>0 
aget 
, 
pop. 
diff. 
(70) 
X 
X 
X 
weight 
oral c. 
oral c. 
reg. day 
reg. 
X 
weight 
season 
day 
season 
weight 
weight 
d>9 
old a.+ 
reg. 
season 
X 
6 
to urn. 
appl. 
(57) 
7 
lying 
down 
stan-
ding 
(57) 
-6.3% -3.9% 
(L) 
X 
-3.4% 
+4.3% 
X 
X 
-3.1% 
(L) 
+3.6% 
(S) 
X 
+5.7% 
(S) 
-6.1% 
(L) 
X 
X 
8 
exercise 
(56b) 
-8% 
+12% 
+17% 
X 
+3% 
++ 
9 
eating 
fasting 
(56b) 
+2% 
+26% 
X 
+12% 
-5% 
X 
X: not studied -: no effect 
x: intralaboratory variability cannot be given as data were converted to logarithms. 
Table 3-8: Literature data on factors affecting normal range values (see text). 
column 1: maximum increase(%) in width of the normal range due to intralabora-
tory variability. The latter is given in brackets, expressed as CV. (25) 
column 2: intraindividual variability, expressed as CV, derived from studies of 
Statland'sgroup (68, 69). 
column 3: idem, derived from studies by Young c.s. (75). 
column 4: effect of age and sex on the normal range. 
column 5: conditions affecting normal range values (weight, regional differences 
(reg.), use of oral contraceptives· (oral c.), time of sample taking per 
season or per time of the day (70 a, b)). 
column 6: the effect of tourniquet application for 3 minutes on the average value 
for 11 individuals (57). 
column 7: the effect of 30 minutes lying down (L) or 30 minutes standing (S) as 
compared to 15 minutP.s sitting down previous to sample taking on the 
average value for 11 individuals (57). 
column 8. the effect of exercise on the average result for 11 individuals (56b ). 
column 9: the effect of a meal two hours before sample taking as compared to 
fasting on the average value for 11 individuals (56b). 
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3.3.2.3. Population differences and differences in sample of the population. 
In general there seems to be little consistency between hospitals as to the proce· 
dure of determination of the normal range. None of the laboratories can be con~ 
sidered to have determined "reference values'' as meant by Dybkaer (18) and Gras· 
beck (31) who introduced this concept: "a set of values of a certain type of 
quantity obtainable from a single individual or a group of individuals corresponding 
to a stated description. This description must be spelled out if others are to use the 
reference values. For each type of quantity a series of reference groups will be 
necessary taking into consideration: age, sex, race, menstruation, previous diet and 
excercise, posture etc."1 ) 
In table 3-8, columns 4 and 5 we have listed the effects of a number of factors 
related to population differences on the range of normal values as they are reported 
in the literature. 
The most recent extensive study on this subject was performed by Winkelman et al. 
(70a,b ). This group published data on laboratory results for appr. 400 clinically 
normal men and appr. 550 clinically normal women, ages 20-49, grouped by sex, 
age, body habitus (weight), regional residence in the U.S. (north/east/south/west, 
urban/rural), season of sample taking and time of the day. Seventy-four of the 
women were on oral contraceptives. Most other studies (15,23,37,45,46,60,63) 
report on age and sex differences only. 
For age and sex differences the studies largely agree on the following: 
increased serumlevels with age are found for urea, glucose, cholesterol and alkaline 
phosphatase. The opposite seems to be true for inorg. P. 
In young people (up to 40 years of age) calcium, inorg. P, urea, cholesterol and 
alkaline phosphatase levels tend to be higher in males as compared to females. This 
tendency persists through higher ages for urea. 
Of the constituents considered in this study sodium. potassium, chloride, creatinine 
and hemoglobin were not studied by the group of Winkelman. 
1 ) This is one of the reasons why for this study the term "normal range" has been used. The 
preference for the term reference interval originated when automated instrumentation became 
available and large screening projects were carried out. The need for specific reference groups 
was felt in the interpretation of test result in these projects. 
Indeed, if it is our ultimate goal (31) to determine true normal human reference values for 
each type of measurable property data from a series of reference groups will be necessary. 
Presently it can be considered misleading systematism to change the name of "normal values" 
determined in e.g. an unspecified group of blood donors into "reference values". 
There is another reason why the term "normal values" is preferred for the present time. In the 
clinical chemistry vocabulary the terms reference methods and - the derived - reference 
values are frequently used. The use of one term for two different concepts, i.e. (a) a normal 
healthy human value and (b) an analytical value measured using a reference method, leads to 
confusion. 
Finally the discussion on what is "normal" is still going on. It is known that blood levels of 
whole populations may change towards pathological levels (e.g. cholesterol in older people). 
While these levels are normally, frequently (76) observed in reference groups, clinicians will 
not consider these levels compatible with optimal health. In time we may want to refer to 
ideal or optimal values (71). 
Figure 3-9: 
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CV of analytical method 
The effect of increasing the C.V. of the analytical method (horizontal axis) on the normal range. 
Figures at the end of each line correspond to the true C.V. of the normal population. The vertical 
axis shows the percentage error of the observed C.V. of this normal population (log scale). 
(Gowenlock and Broughton ref. 29). 
The electrolytes were studied with respect to age and sex by Owen and Campbell 
(46) who found decreasing levels for sodium and chloride with age. For creatinine 
Files and coworkers (23) found higher levels for males as compared to females in 
all age groups. 
For hemoglobin sex and age differences have been studied by various groups (32,55, 
60). All report higher values for males from 20-50 years of age. At higher ages the 
values for males decrease. 
In our study laboratory directors did list the age range of the population sample 
studied (table 3-2). Few, however, indicated the proportion of males and females. 
Laboratory 2 and 5 explicitly state a sample of the population of 20-30 and 20-35 
years of age respectively. No age effects as described in the literature for urea or 
glucose can be found in the normal ranges these laboratories report when they are 
compared with those of laboratories in the group including all age groups in the 
determination of the normal range. Both laboratories, 2 and 5, report relative high 
upper limits for phosphorous. It should be noted however, that laboratory 2 also 
has a systematic analytical bias tending to higher values for this constituent. It 
cannot be decided whether the low normal range for cholesterol reported by labora-
tory 2 is due to systematic bias (table 3-4) or to the fact that young people were 
tested for determination of the normal range. 
All but two laboratories give separate normal ranges for males and females for 
hemoglobin, i.e. for females lower than for males. 
34 
Regional and seasonal differences are reported by Winkelman et. a!. (70a,b) for 
inorg. P, urea, cholesterol, total protein, alkaline phosphatase and LDH (table 3-8 
column 5). In our study no data are available as to the time of the year normal 
ranges were determined. 
Witbin the group of Dutch laboratories it is hard to assign regional population 
differences. There may be some indication in the fact that laboratories I I and I 2, 
located in the same town in the south of Holland both report low upper limits of 
normal for phosphorous. 
In the group of laboratories cooperating with this study normal range values were 
in general determined in hospital personel or blood donors. Only laboratory 4 
studied a group of 1500 out-patients, which may have contributed to the low lower 
limit of normal for potassium, the bigh upper limit for total protein and the wide 
range for hemoglobin in females. 
Also, laboratory 4 is among the group of laboratories reporting upper limits of 
normal for calcium of 2,70 mmol/I and bigher. Of tbis group the high value of la-
boratory 2 can be explained by systematic analytical bias. Laboratory I and 12 
report to have derived normal values from the literature. Laboratory 7 reports its 
-high - upper limit of normal for calcium explicitly for out-patients. This is inter-
esting in view of reports of Yendt and Gagne (72) and Keating (36) who claim that 
if meticulous care is given to methodology and sample taking narrower normal 
ranges can be obtained. Upper limits of normal reported by these authors are 2,58 
and 2,60 mmol/1 respectively. 
3.3.2.4 Technique of sample taking and patient preparation 
Various aspects of the process of sample taking and a number of factors contributing 
to intraindividual variability of serum constituent levels have been studied by Stat-
land and coworkers (6,56a,b,57). 
Tourniquet application (table 3-8 column 6), 30 minutes standing or lying down -
as compared to I5 minutes sitting - previous to sample taking (col. 7), exercise 
(column 8), eating as compared to fasting (column 9), all may influence test results. 
It may surprise that long tourniquet application (3 minutes) did not affect calcium 
determinations in Statland's study. The average result for I I individuals for samples 
taken at I I a.m. (15-30 seconds) and I 1.30 a.m. (3 minutes) did not show a signif-
icant difference. In a separate experiment eight sequential samples of blood were 
taken every 40 seconds during continuous tourniquet application in one individual: 
calcium values rose appr. 3% in the first minute and went up appr. 10% after 200 
seconds. 
For hemoglobin Sunderman eta!. (60) report an increase after exercise. 
In our study the relative wide spread in normal range values for inorganic phospho-
rous and cholesterol observed in this study may not be surprising in view of the 
many possible influences on these determinations listed in table 3-8. All the more 
striking is the small dispersion in upper limits of normal of the majority of labora-
tories for total protein (78-80 gr/1). The same applies for calcium (2.60-2.65 mmol/I) 
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if we exclude the laboratories 4 and 7 that tested out-patients, laboratories 1 and 12 
that derived normal values from the literature and laboratory 2 that showed systematic 
analytical bias. 
In conclusion, differences between hospitals in normal range values can be tentatively 
explained in some cases on the basis of literature data: 
two laboratories where intralaboratory variability is small for potassium report a 
relative narrow normal range. 
a low upper limit of normal for inorganic phosphorous is found by two labora-
tories testing people in the younger age groups. 
one laboratory testing outMpatients reports a high upper limit of normal for calcium 
and total protein, a low lower limit for potassium and a wide range of normal for 
hemoglobin values in women as compared to the other laboratories. 
there is an indication that the upper limit of normal for calcium should not 
exceed 2.65 mmol/1. The higher values reported in this study were obtained for 
out-patients (2 laboratories), were derived from the literature (2 laboratories) or 
were concurrent with systematic analytical bias (!laboratory). 
for cholesterol and inorganic phosphorous the relative wide spread of upper limits 
of normal between laboratories can tentatively be explained by the effects of 
differences in technique of sample taking and differences in condition of the 
individuals tested. 
3.3 .4 lntralaboratory variability 
In table 3-10 column I the data on intralaboratory variability for control materials I 
and II, observed on 10 determinations are presented. In column 2 we have listed 
intralaboratory variability reported by the Quality Assurance Service (QAS) of the 
College of American Pathologists, a project covering daily quality control of about 
1000 hospitals in the United States (38,48). 
No statistical comparison between the two sets of data can be made. The general 
pattern is, that the coefficient of variation for routine intralaboratory variability 
reported by the QAS is larger than that in our study (except for glucose and hemo-
globin), based on sets of 10 determinations in 12 laboratories. Particularly for 
creatinine precision seems to be better in the group of laboratories cooperating 
with our study. 
Although participating laboratories in our study were not informed as to the target 
value for the quality control sera, the materials were known as such. There is evi-
dence (29) that in such - not completely blind - surveys intralaboratory variability 
tends to be lower than the true intralaboratory variability. A recent study by Steele 
c.s. (58) however, reveals no significant difference between masked and unmasked 
samples. Effects of this sort may account for differences between our group and the 
QAS. Within the group however, they are likely to be the same for all participants. 
The significance of differences in intralaboratory variability among the laboratories 
of the group under study was tested by means of Cochran's test (17). This test tells 
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p 
urea 
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Table 3-!0-
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intralaboratory variability in the normal range (CV) 
present study QAS 1975 
median (range) average (range) 
0.9 (0.3-1.4) !.2 (!.1-1.3) 
1.2 (0.5-2.3) 1.9 (1.7-2.1) 
1.4 (0.7-2.4) 2.0 (1.6-2.4) 
1.8 (0.9-2.6) 2.9 (2.3-3.5) 
2.9 (1.5-8.3) 4.3 (2.9-5.7) 
3.1 (!.1-8. 7) 5.3 (3.3-7.5) 
3.1 (1.2-7.1) 7.2 (5.6-9.0) 
5.0 (2.2-7.1) 4.0 (3.7-4.5) 
3.4 (1.7-5.1) 4.4 (3.6-5.3) 
2.3 (0.9-5.6) 2.4 (2.1-2.8) 
5.1 (3.1-14) 7.0 
7.1 (3.0-12) 7.4 
1.9 (0.9-3.7) 1.7'(0.9-4.0) 
Intralaboratory variability observed in this study (median and range) compared to 
average intralaboratory variability (and 2 SD limits) registered by the Quality 
Assurance Service of the College of American Pathologists, which comprises daily 
quality control of about 1000 hospital laboratories (38, 48). 
*average intralaboratory variability and 95% confidence interval for 100 laboratories (38). 
whether or not the variances observed in k groups of n observations differ signif~ 
icantly by testing the ~uotient of maximum variance and summed variances: 
The results were as follows: 
k 
2: 
i = 1 
s·' 1 
differences in intra!aboratory variability were 
non-significant P > 0.05 for Na, Cl, glucose and cholesterol 
significant with 0.01 < P < 0.05 forK and ca!ciwn 
significant with P < 0.01 for P, urea, creatinine, total protein 
aile P-ase, WH and Hb. 
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Chapter N 
NORMAL RANGE VALVES AND ACTION LEVELS APPLIED BY CLINICIANS. 
THE DIFFERENCE BETWEEN LIMIT OF NORMAL AND ACTION LEVEL AS A 
CRITERION FOR REQUIRED ANALYTICAL PRECISION 
4.1 Introduction 
This chapter deals with the answers to the following questions in the questionnaire 
for physicians: 
I a. Which normal values do you apply? 
If you apply different ranges for men and women or for people in different 
age groups, please identify. 
b. Are the normal values mentioned under I a: 
derived from the literature yes/no 
if so, from which textbook or publication? 
concluded from own personal observation? 
based on normal values given by the laboratory? 
other 
yes/no 
yes/no 
c. Suppose you find no abnormalities during a physical examination of a patient 
with ill-defined complaints. You order a number of laboratory tests. Can you 
identify for each constituent a lower and an upper limit which would prompt 
you to an action of the first or second order. 
An action of the first order (Action 1) does include: repeated or additional 
laboratory tests, ECG, X-ray, initiation or change of diet or medication. An 
action of the second order (Action II) is defmed as: hospital admission, imme-
diate treatment. 
4.2 Results 
4.2.1 Normal range values 
When asked for normal range values 31 clinicians out of a total of 63 referred to the 
normal range given by the laboratory, 16 made corrections for one or more constiw 
tuents when asked whether they agreed with the ranges given by the laboratory 
(calcium 8 times, alk. P-ase 7 times, potassium, total protein and LDH 3 times, 
cholesterol and creatinine 2 times). 
Twenty-nine physicians reported normal ranges from memory (5 referred to the 
laboratory's normal range for 1-3 determinations), but only 17 of them listed action 
levels at the subsequent question (!c.). In table 4-1 the normal range values for these 
clinicians are listed. For the remaining 12 clinicians the normal ranges mentioned 
represent action levels (Action 1). 
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Lower and upper limits of normal given by laboratory directors compared to normal range limits 
and action levels given by physicians. 
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2 3 4 
normal values normal values action levels intralab. 
laboratories physicians physicians variability 
M cv n M CV n M cv n cv 
mmol/1 mmol/1 mmol/1 
Na LLN 136 0.7% 12 136 1.7% 18 132 2.7% 59 0.9% 
ULN 146 1.0% 12 144 1.5% 18 147 1.7% 61 0.9% 
K LLN 3.6 8.5% 12 3.7 8.5% 23 3.4 9.1% 56 2.0% 
ULN 5.0 3.6% 12 4.9 8.1% 24 5.2 7.6% 55 1.2% 
Cl LLN 97 1.6% 12 95 3.7% 17 91 5.5% 35 1.4% 
ULN 107 1.3% 12 107 3.1% 16 109 4.1% 33 1.4% 
Ca LLN 2.25 2.9% 12 2.24 4.9% 21 2.16 6.5% 56 1.8% 
ULN 2.67 2.6% 12 2.67 3.8% 23 2.70 4.0% 61 1.8% 
p LLN 0.76 16.6% 12 0.88 17.8% 15 0.78 21 % 40 2.9% 
ULN 1.42 7.9% 12 1.30 16.2% 16 1.53 19.0% 38 2.9% 
urea LLN 2.8 15.0% 12 3.5 30.3% 9 2.7 27 % 15 3.1% 
ULN 7.5 10.1% 12 7.3 14.7% 18 9.1 27 % 44 3.1% 
creat. LLN 57*17.8% 12 58* 22 % 7 0 3.1% 
ULN ll5* 8.0% 12 117* 16.7% 24 120*20 % 57 3.1% 
glue. F LLN 3.8 13.3% 12 4.2 31 % 7 3.4 19.2% 22 5.0% 
PP LLN 4.2 29 % 6 3.2 21 % 22 5.0% 
F ULN 5.9 5.3% 12 6.3 12.6% 9 6.2 14.3% 25 5.0% 
pp ULN 8.7 12.2% 9 8.2 14.5% 34 5.0% 
chol. LLN 3.9 11.7% 12 4.3 17.6% 8 3.4 28 % 15 3.4% 
ULN 7.6 8.0% 12 7.1 8.4% 19 7.7 10.2% 59 3.4% 
t. prot. LLN 62* 3.4% 12 61 12.1% 17 57*13.9% 54 2.2% 
ULN 79* 2.7% 12 79* 6.2% 18 80* 4.5% 52 2.3% 
Hb LLN 7.5 3.4% 10 7.7 6.7% 12 7.3 7.4% 60 1.9% 
LLNd 8.6 1.4% 10 8.1 6.4% 8 8.0 9.2% 43 1.9% 
ULN9 9.8 3.1% 10 8.7 9.7% 8 9.7 6.2% 36 1.9% 
ULN 10.9 2.4% 10 9.7 8.1% 13 10.3 6.2% 52 1.9% 
Table 4-2: For each constituent the average upper and lower limit of normal (ULN and LLN 
respectively) given by the laboratory directors are listed in column 1 as well as the 
dispersion of these limits of normal expressed as 1 CV. In column 2 the averages 
and disperSion of limits of normal given by physicians are listed, in column 3 the 
same parameters of physicians' action levels; n represents the number of labora-
tories {column 1) and the numbers of physicians (column 2 and 3) respectively. 
Median intralaboratory variability expressed as CV is given in column 4. 
*Mean values in mmol/1 except for creatinine (J.Lmol/1) and total protein (gr/l). 
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Three physicians were asked for action levels only, not for normal ranges. 
A number of clinicians take age differences into account. 
cholesterol 26/63 inorg. P 
alk. P-ase 21/63 urea 
creatinine 11/63 total protein 
glucose 7/63 Hemoglobin 
Sex differences are taken into account for: 
Hb 53/63 
creatinine 38/63 (body stature) 
cholesterol 2/63 
alk. P-ase 2/63 
urea 1/63 
6/63 
3/63 
1/63 
1/63 
Although not specifically mentioned in the questionnaire the factor of time and 
technique of sample taking was raised for: 
glucose (fasting) 39/63 
cholesterol (fasting) 7/63 
inorg. P (fasting) 4/63 
calcium (tourn. appl.) 4/63 
t. protein (tourn. appl.) 3/63 
In answer to question ib fifty five clinicians Indicated that they use normal values 
of the laboratory as a guide. Eight derive normal values primarily from own obser-
vation. Seven times literature was mentioned as an additional source. 
In table 4-1 normal range limits reported by clinicians are given together with the 
normal range limits reported by laboratory directors and the action levels given 
by clinicians. In table 4-2 the averages, standard deviations (SD) and coefficients 
of variation (CV) of upper and lower limits of normal and upper and lower action 
levels are given. 
4.2.2 Action levels 
In general limits that would prompt to an action of the first order (repeat of addi-
tional laboratory tests, ECG, X-ray, initiation or change of diet or medication) in 
the given situation could readily be given. A number of physicians interviewed 
stressed the importance of the clinical picture, but in all but three cases figures 
were given that "would not pass unnoticed". For one of these three clinicians this 
question was impossible to answer because the action taken was, for each individual 
case, weighed against the social, psychological and economical consequences for 
the patient. The remaining two physicians would not order any tests in the given 
situation except Hb. When there was some hesitation, the interviewer emphasized: 
''you did have a reason to order the tests". If the age, sex or stature would come 
up relative to deciding action versus no~action the physician was asked to consider 
a normally build man between 30 and 40 years of age. 
Due to the limited period of time available for the interview th~ question as to an 
action of the second order (hospital admission, immediate treatment) was left out 
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in many cases. Hence the data are scarce and will not be presented. This represents 
an area of study of physicians' response to laboratory values which remains to be 
explored. 
In figure 4-1 for each constituent are presented: normal range limits and action 
levels reported by physicians as well as normal ranges given by the laboratories. 
Table 4-2 presents the numerical data: average and CV for lower and upper limits 
of normal and action levels. In the last column of this table intralaboratory variabil-
ity is given expressed as CV. Figure 4-3 gives action levels listed per hospital. The 
upper and lower limits of the normal range given by the laboratory director are 
indicated by arrows. 
In this chapter we will consider for each clinician the difference between either 
limit of normal and the corresponding action level as a measure of the strictness 
this clinician applies in that particular concentration range and hence as a measure 
for required precision for that test at the present time. 
Table 4-4 gives the median values of the differences between limits of normal and 
the corresponding action level for each constituent: column I gives the median 
value for the group of physicians who reported both normal values and action 
levels, column 2 gives the median value for the whole group, thus including the 
clinicians who reported to use the laboratory's normal values. 
In column 3 median intralaboratory variabilities are listed. These are taken from 
table 3-1, where available in the same concentration range as the upper or lower 
limit of normal respectively. 
For comparison of the median difference between upper or lower limit of normal 
and respective action levels with intralaboratory variability the latter is expressed 
as 3 CV. This is the rounded off figure for 2.26 ,f 2 CV which can be considered 
to constitute a significant difference between two individual values, when the variaw 
bility is calculated from ten independent determinations for a controlserum. 
In fig. 4-5 histograms represent the distribution of deviations of action levels from 
the corresponding limit of normal for each constituent. In these graphs 0 represents 
the limit of normal, negative values represent action levels within the normal range, 
positive values action levels outside its limits. 
In our atiempt to analyze the clinicians' attitude towards laboratory results in the 
process of medical decision making it will be of interest to know the probability 
that an action level is comprised in the population of values observed in healthy 
individuals. 
To this purpose we Jist in figure 4-5 the P-value of the action levels in the graph, 
assuming the normal range to be the 95% limits of variation of a Gaussian distribu-
tion. 
We assumed the width of the normal range to comprise for: 
Na 10 mmol/1 creatinine 60 llmol/1 
K 1.6 mmol/1 glucose 2.0 mmol/1 
CJ I 0 mmol/1 cholesterol 3.0 mmol/1 
Ca 0.40 mmol/1 t. protein 20 gr/1 
P 0.80 mmol/1 Hb 2.0 mmol/1 
urea 4 mmol/1 
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Figure 4~3: 
Histograms of action levels given by clinicians per hospital (numbered 1 through 12). The labora-
tories' upper and lower limits of normal are indicated by arrows. 
At the bottom of each figure histograms are given of accumulated data. 
The histograms for a number of constituents are presented in addendum II. 
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Figure 4~3 cont. 
4.3 Discussion 
The following points will be discussed respectively: 
the dispersion of normal range values and action levels among clinicians. 
action levels as related to nonnal range values; the difference between limit of 
normal and action level as a criterion for required analytical precision. 
4.3.1 Dispersion of normal range values and action levels among clini-
cians. 
Figure 4-1 and table 4-2 show us that the dispersion of limits of nonnal given by 
the laboratories is in general smaller than the dispersion of clinicians' upper and 
lower limits of nann a!. 
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It is striking that the - relatively small - group of clinicians that mentions normal 
limits as well as action levels tends to apply more strict limits of normal in many 
cases: particularly for sodium, potassium, chloride and inorganic phosphorous 
physicians give lower upper range limits than the laboratories (fig. 4-1 ). 
Laboratory results that prompt the clinician to action vary even more among physi-
cians than limits of normal. More than once upper and lower action levels overlap: 
a value that urges one physician to take action because it is too low, strikes another 
physician, sometimes in the same hospital, as a disturbing high result. Also we note 
the clinician's preference for figures ending on 0 or 5 and for even numbers. Evidently 
there is a need for simplification of the multitude of figures and data that reach the 
physician in the course of a diagnostic process. 
Inspection of fig. 4-3 shows us that variation between physicians within one hospital 
is often as large as the variation between clinicians of different hospitals. Hence it is 
extremely difficult to determine whether clinicians respond to the differences in 
normal range values reported by the laboratories that could be ascribed to factors 
like systematic analytical bias, differences in samples of the population etc. (Chap-
ter Ill). 
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On detection of the large discrepancies in clinician's action levels one question that 
rises is: can intralaboratory variability account for the differences observed. In other 
words, is intralaboratory variability such, that the different values reported as action 
levels in fact cannot be differentiated. 
Comparing the CV of the dispersion of clirjcians' action levels with the CV of 
intralaboratory variability (table 4-2) in this group of laboratories it can be seen 
that for the electrolytes and for the upper limits of total protein and cholesterol 
indeed intralaboratory variability is even I<> to \6 of the variability in action levels. 
There must, however, be other reasons for the observed differences in judgement 
between clinicians. 
Murphy ( 43) gives seven meanings of the concept "normal": 
-~cc---c-''CC"C:":C"'":::"_~-c--l--c-'"C:':C"':C'"'c:':_":::"c___l_:'_c"!"•blo Term 
I, Ha,·ing probability density function 
1 [ '("-')'] f(x) = ;-;;-exp --2 --uv2n u 
(predicated of a metrical character) Statiotics 
2 1-!ost represen"tative of its class . . D{hl~'fo;," .";:'~jnce 
~: ~o0~1ms~~i~<t~~~~~i~:1 ~~jt• class.. . . Descriptive science 
reproduction 
.1. Carrybg no penalty . 
6_ Commonly aspired to 
7. Most perfect of its class 
Genetics, operations re· 
search, quality control. 
etc. 
Clinical medicine 
Politics, sociology, etc. 
Metaphysics, esthetics, 
morals, etc 
Gaussian 
Average, median, 
modal 
Hahitual 
Optimal or 
"fitte;t" 
Innocuous or 
'I harmless Con,•entional 
Ideal 
The clinician in the process of arriving at a diagnosis "normal" or "abnormal" may 
have at least 5 of these seven meanings in mind, they are: 
most representative ofit's class 
frequently encountered in it's class or not uncommon 
most suited to survival and reproduction 
carrying no penalty or harmless 
most perfect ofit's class or ideal 
In this regard it is not surprising that normal range levels given by clinicians vary, 
since each of them will set different priorities and will emphasize different aspects. 
There is in practice a world of difference between "most commonly encountered", 
"carrying no penalty" and "ideal". 
Apart from the differences in interpretation of the word normal each physician 
will, as Murphy stresses (43) sample from different populations and for that 
reason the cut-off points between normal and abnormal will differ. An inter-
esting example is given by Bawkin (3): " ... surveyed a group of 1000 children, 
eleven years of age, from the public schools of New York City and found that 61% 
of these had had their tonsils removed. The remaining 39% were subjected to exami-
nation by a group of physicians, who selected 45% of these for tonsillectomy and 
rejected the rest. The rejected children were re-examined by another group of physi-
cians, who recommended for tonsillectomy 46% of those remaining after the first 
examination. When the rejected children were examined a third time, a similar 
percentage was selected for tonsillectomy, ... " 
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2 3 
median differences between lower or upper median intra-
limit of normal and action levels for lab. variability 
expressed as 
physicians naming all physicians 3 cv 
own normal range 
N N 
Na LLN 5 mmol/1 3.7% 15 4 mmol/1 2.9% 51 2.7% 
ULN 4 mmol/1 2.7% 16 2 mmol/l 1.4% 51 2.7% 
K LLN 0.35 mmo1/1 9.7% 20 0.40 mmol/l 11.1% 50 6.0% 
ULN 0.30 mmol/1 6.0% 20 0.20 mmo1/1 4.0% 50 3.6% 
C1 LLN 5 mmol/1 5.2% 11 5 mmol/1 5.2% 26 4.2% 
ULN 4 mmol/l 3.7% 10 3 mmol/1 2.8% 25 4.2% 
Ca LLN 0.10 mmol/1 4.4% 16 0.05 mmol/1 2.2% 49 5.4% 
ULN 0 mmol/1 0 % 23 0 mmol/l 0 % 53 5.4% 
p LLN 0.07 mmol/1 9.2% 10 0 mmol/1 0 % 53 8.7% 
ULN 0.32 mmol/1 23 % 8 0.15 mmol/1 10.6% 32 8.7% 
urea LLN 0.4 mmol/1 14.3% 4 0 mmol/1 0 % 13 9.3% 
ULN 1.6 mmol/1 21 % 14 1.3 mmol/1 17.3% 49 9.3% 
creat. LLN 9.3% 
ULN 0 ,umol/l 0 % 19 0 !ffil01/1 0 % 51 9.3% 
glue. LLN 0 mmol/1 0 % 11 0 mmol/1 0 % 23 15.0% 
ULN 0 mmoljl 0 % 15 0 mmol/1 0 % 33 15.0% 
chol. LLN 1 0.25 mmol/1 6.4% II 10.2% 
ULN 0 mmol/l 0 % 18 0 mmol/l 0 % 51 10.2% 
t. prot. LLN 5 gr/1 8.1% 12 2 gr/l 3.2% 44 6.6% 
ULN 5 gr/1 6.3% 12 0 gr/1 0 % 44 6.9% 
ALP LLN 15.3% 
ULN 0 % 21 0 % 51 15.3% 
LDH LLN 21 % 
ULN 10.0% 18 9.0% 43 21 % 
Hb LLN 0.3 mmol/l 4.0% 11 0 mmol/1 0 % 46 5.7% 
ULN9 2 0 mmol/l 0 % 23 5.7% 
LLNd 3 0.5 mmol/1 5.8% 27 5.7% 
ULN 0.5 mmol/1 4.6% 12 0 mmol/I 0 % 43 5.7% 
Table 4-4: Median differences between lower (LLN) and upper (ULN) limits of normal and 
respective action levels expressed in units of measurement and in percentage of 
the average limit of normal related to median intralaboratory variability observed 
in this study, expressed as 3 CV (column 3). The median differences between 
limit of normal and action level (ranges are given in figure 4-5) for physicians naming 
own normal values are listed in column 1, those for the whole group, including the 
cases where the laboratory's limit of normal were used for calculations, in column 2. 
Uncorrected median differences (see text for explanation) for Na (LLN): 3 mmol/1, 
K (LLN): 0.35 mmo1/1, P (LLN): 0.05 mmol/l. 
As for action levels the differences in judgment between physicians can be expected 
to be even more outspoken for the following reasons: 
·- while for the answer to the question "what do you consider normal" each consti-
tuent can be considered separately, the decision to take action is taken only after 
considering a multitude of aspects. Besides results of physical examination and 
case history also the consequences and chance of success of the action will play 
a role. 
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subspecialization occurs even in the smaller hospitals. It encourages clinicians to 
be more keen for some determinations and less for others. 
- for each clinician the dependence on laboratory results in arriving at a diagnosis is 
different in relation to the clinical picture. Whereas some see laboratory data 
merely as an aid to confirm their diagnostic hypothesis, others are convinced that 
every deviation from the normal, the frequently observed or ideal pattern should 
be investigated thoroughly as a possible indication of disease. 
Although the existence of variations in action levels between clinicians may be 
plausible, a discussion among physicians on this subject is needed. We refer in partic-
ular to the overlap of upper and lower action levels and to the question of importance 
of laboratory data in relation to other observations. 
Differences in interpretation of observations in medical practice have been reported 
in the literature (7 ,11,16,22,49 ,53,64,66,74). 
For example, West concludes (64): "Under certain common circumstances, some 
diabetologists would classify as normal more than half of the one- and two-hour 
(glucose) values considered to be abnormal by other well qualified diabetologists". 
With the advance of computer-aided multivariate analysis of observations important 
in diagnosis (2, 33, 44, 50, 54) the determination of cut-off points is indicated and 
agreement should be reached at this point (7). 
In the mean time the variations in action levels observed interfere with the conclu-
sion one would want to make from the clinical laboratory point of view. 
In fact, this may well be the main reason why this subject has remained untouched 
for so long. Nevertheless, the data obtained can be usefull to examine the main 
question of this study: to which determinations should- from the point of view of 
the practicing physician - priority be given for an effort to improve analytical 
performance. 
4.3.2 Action levels and normal range limits. 
In this study clinicians' action levels are in many cases not similar to the limits of 
normal set by themselves or by the laboratory (table 4-2, fig. 4-1 ). In other words, 
in the process of distinguishing the diseased individual from the normal population 
the clinician often takes less than the - ''usual and convenient" (24) - 1 in 20 
chance of erroneously classifying someone diseased as being healthy. This is also 
demonstrated by the P values in figure 4-5 indicating the probability that an action 
level forms part of the population of values observed in healthy individuals. In other 
cases he chooses to be more strict and evidently does not want to take the risk of 
missing a diagnosis. For a number of constituents his attitude in this respect is 
different in the upper as compared to the lower decision range. From fig. 4-5 
and table 4-4 we see for example, that clinicians tend to be more strict for the upper 
limits for potassium and calcium than for the lower limit. The opposite seems to be 
true for inorg. phosphorous. Also, lower limits for creatinine, urea, cholesterol and 
the enzymes are not of great interest to the majority of this group of physicians. 
ln fact, Murphy and Abbey (42) express the view, that the use of the normal range 
is an oversimplification. To put it in extremes "No competent clinician ever makes a 
Nc - LLN 
N lower limit cf normal 
within N.R. I outside N.R. 
12 
8 
4 
Nc - ULN 
N 
12 
upper limit of normal 
within N.R. I outside N.R. 
4 
-6 -4 
P: o13 
Urea - LLN 
N 
41 .khd 
-2 -I 0 I 2 
p, ,, 
·"' 
.. , 
Ureo - ULN 
N 
12 
8 
4 
0 2 3 
p, 
·' ·"'' 
,., 
Creot. ULN 
N 
12 
8 
mmol I 
mmol/1 
4 mmol/1 
4 5mmol I 
.o'gl 
50 
12 
12 
8 
4 
K - LLN 
N 
-.6 
p, 
-.4 
K- ULN 
N 
p, 
" 
Glue.- LLN 
-.2 
N j 41 n 
-I 0 
p, 
"" 
Glue.- ULN 
N 
12 
8 
-I 
p, 
"' 
ALP -ULN 
N 
12 
0 
.12l .1a1 ,,, 
025 oo, .. , 
Q I,,R/;h 
"" mmol/1 I 2 
·~ ,,, 
,, o'•, 
% 
12 
4 
12 
4 
12 
12 
CL - LLN 
N 
-4 -2 
p, 
Cl- ULN 
N 
-4 -2 
p, 
P- LLN 
N 
P- ULN 
N 
-.2 -.1 
,, 
Figure 4-5: 
6 mmol I 
3 
51 
14 mmol/1 
mmol I 
mmol I 
Co - LLN 
N 
12 
8 
4 
Co - ULN 
N 
12 
T. Prot.- LLN 
N 
12 
8 
4 
12 
4 
p, 
T. Prot.- ULN 
N 
-10 
P. 
mmol I 
9' 
Histograms of differences between lower (LLN) and upper (ULN) limit of normal and correspon-
ding action levels. In each figure "0" represents the limit of normal, negative values represent 
action levels within the range of normal values, positive values action levels outside these limits. 
m: action levels of physicians reporting own normal ranges. 
52 
Hb - LLN Chol.- LLN 
N 
N 
12 
41 8 n CJ CJ 
'? CJ 4 -1 0 mmol/1 
p, 
"' 
,,, 
-2 
-1 mmol/1 
" 
,, 
.023 _,, Chol.- ULN 
Hb - ULN 9 N N 
t 0 12 n [l 0 -1 0 2 mmol/1 4 
" ·' 
.023 .043 .<II 
N Hb-LLNd 0 { p, "' ,., D LDH - ULN D D 0 N 
-1 0 1 2 3 mmol/1 
" 
_, 
.023 
·'" 
.CIIll 
Hb- ULN 
N 12 
·I r4:L 4 4 D IZll 
-2 -1 0 1 2 mmol I 
" ·' 
.Q23 _,., .<1\ 
Figure 4-5 cont. 
53 
diagnosis on the basis of whether or not the patients value lies within the "normal 
range" " ( 42). 
Clearly the clinical question is not primarily whether or not a certain value is beyond 
the limits of normal, but rather whether or not the value found belongs to an alterna-
tive to health that calls for action. (39, 42, 47) 
The answer to this question is not related to the width of the normal range itself 
but rather to the location of the range of valuos in diseased subjects as compared to 
the range of values in healthy individuals. 
Consequently, in order to derive data on clinical requirements for analytical perfor~ 
mance in the critical decision ranges between normal and pathological results we 
propose to consider the difference between limit of normal and the respective action 
level as a measure. 
Laboratory performance, firstly with respect to precision has to be such, that a 
distinction can be made between action level and limit of normal. According to 
the foregoing discussion this appears to be a better approach than the requirement 
that analytical error should not exceed a proportion of the normal range (14, 61a,b, 
62, 77). If the latter requirement is met, it only tells us about the laboratory's 
ability to distinguish the upper limit from the lower limit of normal, which is clini-
cally irrelevant at present. 
Also the approach of Young, Harris and Cotlove (75), Statland (69) and Steele (58) 
to relate allowable analytical error to L'1traindividual variation is not applicable to 
the most common situation of wanting to distinguish the diseased individual from 
the normal population. 
The relation of precision to intraindividual variability is, of course, relevant in 
preventive medicine. 
Before drawing any conclusion as to requirements for analytical performance from 
the differences between limits of normal and respective action levels we will take 
a closer look at the distributions of these differences first. 
While a group of clinicians (shaded in fig. 4-5) gave normal values as well as action 
levels, the majority indicated to apply the laboratory's normal values. Hence in these 
cases in the calculation of the differences between action level and limit of normal 
the laboratory's normal values have been used. The distributions of shaded area's 
(own normal values) and clear area's (laboratory's normal values) in fig. 4-5 do not 
differ considerably in most cases and median values (table 4-4) show the same 
pattern and are fairly close in the two groups. The number of negative values (action 
level within the normal range), though small, is higher in the group where action 
levels were related to the laboratory's normal range values. 
In chapter lli (sections 3.3.1 and 3.3.2) we discussed the differences in normal 
ranges reported by the laboratories and in a number of cases these differences could 
be tentatively ascribed to specific causes: systematic analytical bias, sample of the 
population choosen for determination of the normal range, patient and sample prepa-
ration, etc. Some of these causes are relevant for clinicians and others are not. By 
revisiting the observations of chapter III we may find some explanations for extreme 
values in the frequency distributions of differences between action levels and limits 
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of normal of fig. 4-5. 
Since in fig. 4-5 action levels are related to the corresponding limit of normal by 
setting the latter at zero, systematic bias between laboratories can be considered to 
be cancelled out. For the enzymes, for which systematic analytical bias is considerable, 
differences between upper limit of normal and action level are expressed as a percen-
tage of the upper limit of normal. 
As to the possible regional population difference for phosphate in laboratories II 
and 12 we note that the low upper limits of normal are followed closely by physicians 
in these hospitals. In hospital 12 three out of four clinicians apply action levels even 
lower than the upper limit of normal given by the laboratory (see also fig. 4-3). 
For these cases no extreme values in fig. 4-5 are expected. 
Clinicians in hospital 4 ignore however, the laboratory's normal range determined 
on out-patients for the - low - lower limit for potassium and for the - high -
upper limit for total protein. 
Four out of six clinicians in hospital 12, which derived its - high - upper limit of 
normal for calcium from the literature report action levels lower than that limit. 
The majority of physicians in laboratory 5, which found a high normal range for 
inorganic phosphorous in young individuals report action levels far beyond the 
lower limit of normal. 
Two clinicians in hospital 10 report lower action levels for sodium, within the 
normal range given by the laboratory. This laboratory showed a high systematic 
analytical bias in the survey, that was not reflected in the normal range (table 3-4). 
The upper limit of normal for creatinine in laboratory 6 is high as compared to 
other laboratories. Five clinicians in this hospital report action levels lower than the 
upper limit of normal ( 4 negative values in fig. 4-5). 
The three extreme large differences between upper limit of normal and action level 
for creatinine (62, 45 and 45 11mol/l respectively are reported by American clinicians 
who evidently apply different criteria. 
In the foregoing cases extreme negative or positive values were found for the differ-
ences between upper or lower limit of normal and the corresponding action level. 
They are indicated in fig. 4-5. In fact these values can be omitted. This does however 
cause changes in the median values of the distributions only in a few cases. In table 
4-4 the corrected median values are given. The uncorrected values are mentioned in 
the legend. 
When we now compare the median difference between limit of normal and action 
level expressed as a percentage of the limit of normal (table 4-2) with intralabora-
tory variability (table 44) we see that for a number of constituents laboratory 
precision seems to meet the median requirement if 3 CV is used as a measure of 
intra!aboratory variability. This is the case for potassium, inorg. phosphorous and 
urea. For sodium and chloride laboratories are just short of good performance. 
The requirements are not met for calcium, creatinine, glucose, cholesterol, alk. 
P-ase, LDH, total protein and hemoglobin. 
The requirements for laboratory performance found are very strict and where they 
number zero (limited by the number of decimal points) they are extremely hard to 
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achieve. The results do indicate, however, a pattern of priorities to be set. In chapter 
VII we will discuss these requirements for the laboratory in the decision range 
together with those based on a significant change in a patient tn the near abnormal 
range in view of clinicians' satisfaction with test results. 
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ChapterV 
MEDICAL SIGNIFICANT CHANGES IN THE INDIVIDUAL PATIENT RELATED 
TO ANALYTICAL PRECISION. 
POSSIBLE CAUSES OF VARIATION IN LABORATORY RESULTS. 
SATISFACTION WITH LABORATORY PERFORMANCE. 
5 .I Introduction 
In this chapter the answers to the following questions will be discussed: 
II Suppose you find in a patient under your treatment the laboratory result 
given in the table: 
Na K Cl Ca P urea creal. glue. chol. !.prot. ALP LDH Hb 
119 2.4 118 2.85 2.52 13.4 230 14.0 9.1 48 5.6 
mmol/1 Mmol/1 mmol/1 g/1 mmol/1 
You follow the course of this patient and/or the effect of treatment. Please 
circle the value, that would represent a signicant change, in these cases improve-
ment: 
Na K 
120 2.5 
121 2.6 
Cl Ca 
117 2.80 
116 2.75 
P urea creat. 
2.45 12.6 221 
2.38 11.8 212 
glue. chol. 
13.5 8.6 
12.8 8.2 
!.prot. ALP LDH Hb 
50 5.9 
52 6.2 
Please answer this question for each constituent separately. 
III There are a number of factors responsible for the day to day variability oflabo-
ratory data. We have the biological variation in the patient. laboratory error. 
handling of the sample (e.g. technique of sample taking, storage) and possibly 
other factors. Can you indicate to which extent these factors contribute to 
this variability? 
++;:very great. +:great, ±:moderate, ~:none. 
~ biological ++/+/±/~ 
~ laboratory error ++/+/±/~ 
~ handling of the sample ++/+/±/~ 
~ other ++/+/±/~ 
IVa For which constituents do you feel a great accuracy of the laboratory is needed; 
in other words, are there laboratory tests for which you would say: "!could do 
better work, if the laboratory did a better job". 
b Please identify the degree of accuracy desired (state two values between which 
you want to distinguish). 
5.2 Results 
5 .2.1 Medical significant changes in a patient 
As a starting value in the question "what do you consider a significant change in a 
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patient" a value was chosen in the near abnormal range, so that: 
a. the answer would not be influenced by the nearest limit of normal 
b. intralaboratory variability would be known in the same concentration range. 
Hence the concentration levels of the control sera were taken into account. 
As a result most starting values were, though not near to the normal range, close to 
the range of action levels and thus close to the most critical medical decision range, 
particularly for potassium and cholesterol. The starting values for sodium, inorganic 
phosphorous and creatinine however, were for most clinicians well outside this 
range. 
Due to methodological differences between laboratories results for enzyme analyses 
may have numerical values that are considerably different between hospitals and 
thus a starting value could not be fixed ahead. During the interview a value was 
chosen 1\6 to 2 times the upper limit of normal mentioned at question Ia. 
In figure 5·1 the answers given to the question of a medical significant change in a 
patient are given in histograms. The initial value is at the far left of each graph. An 
arrow indicates the median intralaboratory variability at this level expressed as 3 SD. 
This is the rounded off figure for 2.26 J2 SD, which can be considered to constitute 
a significant difference between two individual values when the variability is calculated 
from ten independent determinations for a controlserum. In table 5-2 the average 
significant change from the initial value is given in units of measurement as well as 
in percentage of the initial value, together with median intralaboratory variability 
(3 CV). 
The dispersion of clinicians' answers and intralaboratory variability both expressed 
as I CV are given in column 4 and 5. 
In figure 5-3 the medical significant changes are listed per hospital. Here each labora-
tory's intralaboratory variability (3 SD) is indicated as a bar. The values given by 
clinicians who, in question IV of the questionnaire reported to be dissatisfied with 
laboratory performance for that test are shaded. 
5 .2.2 Possible causes of variation in laboratory results 
When asked for the cause of day-to-day variations in laboratory results a general 
answer was given by a number of clinicians. Many times the question was answered 
for individual constituents separately. 
Biological variation was mentioned 11 times, laboratory error 9 times and sample 
handling 12 times as most important factor. 
Biological variation was mentioned for glucose (16 times), cholesterol (7 times), 
inorganic phosphorous, total protein and calcium (5 times) and sodium and urea 
( 4 times). Eight other constituents were named 1 or 2 times. 
The answers referred to both dietary conditions and physiological variations. Labo-
ratory error was mentioned as the most essential cause of variation for creatinine (9 
times) and calcium ( 4 times). Eleven other constituents were named 1-3 times. 
For potassium (19 times), total protein (II times), hemoglobin (10 times), calcium 
(8 times) and LDH ( 6 times) sample handling, i.e. tourniquet application, hemolysis 
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Figure 5-1: 
Medically significant change in a patient. 
•: initital value 
Y: median intralaboratory variability (3 SD). 
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Na 
K 
Cl 
Ca 
p 
urea 
creat. 
glue. 
chol. 
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ALP 
LDH 
Hb 
1 
initial value 
119 mmol/1 
2.4 mmol/1 
118 mmol/1 
2.85 mmol/1 
2.52 mmol/1 
13.4 mmol/1 
230 umol/1 
14.0 mmol/1 
9.1 mmol/1 
48 gr/l 
5.6 mmol/1 
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2 
average medically 
significant change 
5.1 mmol/l 4.3% 
0.38 mmol/1 15.8% 
5.2 mmol/1 4.4% 
0.13 mmol/1 4.6% 
0.25 mmol/1 9.9% 
2.46 mmol/1 18.4% 
29.9 ~mol/! 13.0% 
2.17 mmol/1 15.5% 
1.33 mmol/1 14.6% 
6.9 gr/! 14.4% 
17.6% 
22.2% 
0.75 mmol/1 13.4% 
3 4 5 
median intra- dispersion median 
lab. var. (JCV) answers intralab. 
clinicians var. (lCV) 
(lCV) 
3.6% 1.2% 1.2% 
6.0% 4.4% 2.0% 
4.2% 1.7% 1.4% 
5.4% 2.7% 1.8% 
8.1% 4.5% 2.7% 
8.4% 8.9% 2.8% 
9.3% 8,0% 3.1% 
14.4% 7.9% 4.8% 
10.2% 5.9% 3.4% 
6.6% 4.2% 2.2% 
12.6% 7.9% 4.2% 
13.8% 10.1% 4.6% 
5.7% 4.6% 1.9% 
Table S-2: Medically significant change in the individual patient related to intralaboratory 
variability. Dispersion of clinicians' answers. 
column 1: initial value 
column 2: average medically significant change expressed in units of measurement 
and in percentage of the initial value. 
column 3: median intralaboratory variability (3 CV). 
column 4: dispersion of clinicians' answers (1 CV). 
column 5: median intralaboratory variability (1 CV). 
etc. were thought to contribute considerably to variation in laboratory results. Six 
other constituents were mentioned once in this respect. 
5.2 .3. Satisfaction with laboratory performance. 
Fifty-one out of 63 physicians interviewed expressed their concern for the quality 
of laboratory performance for one or more constituents: Creatinine was mentioned 
21 times, hemoglobin 18 times, calcium 19 times, total protein 12 times (protein 
spectrum 4 times), various enzymes 31 times ("enzymes" 4 times, LDH 8 times, 
alk. P-ase 6 times, others 13 times), inorganic phosphorous and cholesterol 5 times. 
Seventeen other tests were mentioned 14 times. Several physicians stressed the 
fact, that sample handling plays a role in the reliability of laboratory results for 
hemoglobin and calcium. 
Thirteen times faulty administrative procedures, clerical errors, delay in reporting, 
sample exchange and blunders were brought up as a source of aggravation. 
These data will also be discussed in chapter VI, section 6.3.1. 
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5.3 Discussion 
The following subjects will be discussed respectively: 
the dispersion among physicians of reported medical significant changes 
medical significant change as related to intralaboratory variability, satisfaction 
with laboratory performance and causes of variation in laboratory results. 
5 .3 .1. Dispersion of answers among physicians. 
When we consider figure 5~1 we see that there is some dispersion in the answers 
of clinicians to the question: "what do you consider a medically significant change 
in a patient". This dispersion is of the same magnitude in some cases but in most 
cases smaller as compared to the dispersion we saw for clinicians action levels ( cf. 
fig. 4-3, totals). 
Indeed the decision that a constituent level is medically significant different from 
a previous value in the same patient seems less complicated than the decision that a 
value, outside the range of normal values calls for action. In the latter case it is not 
only a matter of determining that a certain value does not belong to the range of 
values frequently seen, but more so, the value should fit in a diagnostic pattern and 
so lead to action. 
[n the case of a change in an individual patient it will be easier to consider each 
constituent separately and the decisionmaking variables thought to be responsible 
for dispersion of action levels in chapter N (page 48, item 1), i.e. the variety of 
factors involved in the decision "to take action") will not count as heavily here. 
The other reasons mentioned in chapter IV for differences in action levels also help 
to account for the dispersion among clinicians of medical significant changes in a 
patient: 
sub specialization usually leads to an increased interest in particular tests. 
the dependence on laboratory results as compared to the clinical picture differs 
from clinician to clinician. Some wait confirmation of their hypothesis only, e.g. 
the expected effect of their treatment. Others, in a similar setting, will set treat-
ment according to the laboratory result. 
Finally, laboratory variability contributes to the variability in answers to the question 
on medical significant changes. 
Particularly with respect to the last poU,t it is interesting to see in table 5-2, column 4 
and 5, that median intralaboratory variabillty is close to the variability of clini-
cians' answers. In other words, when the majority of clinicians reports for example 
for calcium, starting value 2.85 mmol/l, values ranging from 2.80 to 2.60 mmol/1 as 
concurrent with a medical significant change we have to realize, that the average 
hospital laboratory cannot adequately differentiate in this range. 
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Figure 5-3: 
Histograms of constituent levels representing a medically significant change in a patient, given a 
certain initial value. 
liB : initial value 
~ : answers of physicians not satisfied with the determination 
c=:::;J: intralaboratory variability (3 SD). 
5.3 .2. Average medical significant change and req uirem en ts for labora-
tory performance. 
Let us now tum from the dispersion observed among physicians' answers to the 
average medical significant change. How does the average medical significant change 
in a patient relate to median intralaboratory variability and how is the situation 
per hospital? 
From table 5-2, column 2 and 3 we conclude, that median intralaboratory precision 
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Figure 5-3 cont. 
is more than adequate to record shanges in the individual patient in the near abnor-
mal range for sodium, potassium, urea, creatinine, cholesterol, total protein, alk. 
P-ase, LDH and hemoglobin, just adequate for chloride, inorg. phosphorous and 
glucose and inadequate for calcium. 
In figure 5-3 the answers are split up per hospital and the question rises: do clinicians 
working with a hospital laboratory with small intralaboratory variability respond by 
reporting small medical significant changes in the individual patient? The fact that 
clinicians' answers vary to the degree they do does not facilitate the search for an 
answer to this question. 
In chapter Ill, section 3.3. we found that for all constituents but Na, Cl, glucose and 
cholesterol the variabilities found in various hospitals were significantly different. 
For none of these constituents a positive correlation was found between the degree 
of analytical variability of the laboratory and the average significant change in a 
patient mentioned by physicians (rank correlation test of Spearman (17)). Yet some 
remarks can be made when we consider fig. 5-3 and take into account clinicians' 
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Figure 5-3 cont. 
answers to another question of the questionnaire: for which constituents do you feel 
greater accuracy is needed. Greater reliability of laboratory results was said to be 
most needed for calcium, creatinine, Hb, total protein and "enzymes". 
Three out of four clinicians who are not content with the potassium detennination 
work in hospital 6 with highest intralaboratoiY variability (SD: 0.36 mmol/1). 
In hospital 5 and 6 with highest intralaboratory variability for calcium aerermina-
tions 3 out of 7 (43%) and 4 out of9 (44%) clinicians respectively were not satisfied 
with the quality of calcium analyses. When we rank hospitals according to percentage 
of clinicians dissatisfied with calcium determinations these two hospitals rank 9 and 
10 out of 12. Hospital 7 with lowest intralabora!Ol)' variability is one out of three 
hospitals where none of the clinicians is incontent. 
For inorganic phosphorous laboratol)' 12 ranks 8/12 for intralaboratol)' precision 
and 3 out of 4 clinicians who declare to be dissatisfied with phosphorous determina-
tions work in this hospital. 
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Figure S-3 cont. 
For creatinine we see, that clinicians in hospital 1 and 9, with highest intralaboratory 
variability (SD: 30 and 36 /lillOl/1 respectively, (other laboratories of the group, 
SD: 6-23 lffi10l/l) indicate largest average medical significant changes, 54 and 47 
J.!mol/1 respectively as compared to 23-38 J.ill10l/l in the other hospitals. In hospitals 
3, 6 and 9 with 5th, third and first highest intralaboratory variability over 60% of 
clinicians is dissatisfied with laboratory performance of this test. Other hospitals: 
0-50%). 
No peculiarities as mentioned above were seen for urea, total protein, hemoglobin, 
Alk. P-ase or LDH. 
For hemoglobin, total protein and the enzymes a considerable number of physicians 
voiced dissatisfaction with the determination, as was the case for calcium and creati-
66 
nine, but no positive correlation could be found for these tests between e.g. the 
number of dissatisfied clinicians per hospital and intralaboratory variability. This 
may indicate that dissatisfaction with the laboratory for these tests is caused by 
other factors e.g. technique of sample taking, patient preparation or unrecognized 
biological variations. 
Summarizing we may conclude that for the follow up of the individual patient in 
the near abnormal range laboratory performance in general is inadequate for calcium. 
Strictly taken, also chloride, inorg. phosphorous and glucose determinations need 
improvement. Differences in precision among hospital laboratories are in some cases 
discerned by clinicians. In hospitals where laboratories have larger intralaboratory 
variability clinicians may apply a wider medically significant change and more 
clinicians may be dissatisfied with the precision of the determination in comparison 
with clinicians working with more precise laboratories. This situation has been 
demonstrated for potassium, calcium, inorg. phosphorous and creatinine. Clinicians' 
dissatisfaction with total protein, hemoglobin, alk. P-ase and LDH determinations 
may be related to technique of sample taking or patient preparation. 
The conclusion with regard to requirements for the laboratory from the clinical 
point of view derived in this chapter will be related to those derived in chapter N 
in chapter VIII. 
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Chapter VI 
CLINICIANS' ATTITUDE WITH REGARD TO ORDERING OF REPEAT TESTS 
AND CONSULTATION OF THE LABORATORY IN CASE OF AN UNLIKELY 
RESULT. 
FAST SEMI-QUANTITATNE TEST RESULTS. 
MOLECULAR UNITS IN MEDICAL PRACTICE. 
6.1 Introduction 
In this chapter the answers to the following questions of the questionnaire will be 
discussed: 
Va. Do you ever order a repeat test - on a new sample - before making a medical 
decision? always/often/ sometimes/ never 
b. Suppose the value reported for a repeat test is substantially different from the 
first time. How do you proceed: 
you order the test for a third time always/often/sometimes/never 
you consult with your laboratory always/often/sometimes/never 
you disregard the value that is least likely in the given situation 
always/often/sometimes/never 
other 
VI Are there blood constituents - possibly others than the ones named in the 
table - for which you would prefer a fast semiquantitative result (within an 
hour) over an accurate value on longer terms? 
Please state the degree of accuracy desired (two values between which a distinc-
tion is to be made). 
IX. a. Does your laboratory report in molecular units? yes/no 
b. If so, since when? 1970/1971/1972/1973/1974/1975 
c. How long did it take you to get used to the new units? 
< 3 months/3-12 months> I year 
d. Have molecular units enabled you to give better treatment to patients? 
yes/somewhat/no 
e. Have molecular units given you more insight into biochemical processes? 
yes/somewhat/no 
f. Do you convert mmol/1 into mg% before making a medical decision? 
always/often/sometimes/never 
g. Do you convert mg% e.g. from the litterature into mmol/1 for optimal inter-
pretation? always/often/sometimes/never 
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6.2 Results 
6.2.1. Repeat test requests and proceeding in case of a highly unlikely 
result. 
As to the question whether a repeat test is ordered before a decision is made the 
answers were as follows: 
27/63 clinicians order repeat tests always or often. 
17/63 clinicians report to always ask for a repeat test if the first result is incompat-
ible with their expectations. 
9/63 clinicians indicate that the frequency of repeat tests ordered is primarily 
dependent on the importance of the decision to be made on the basis of 
the laboratory result. 
10/63 clinicians seldom or never reorder tests. 
When a result of a repeat test differs considerably from the first result the procedures 
followed are: 
24/63 clinicians request a third test to determine which of the two divergent results 
was correct, or reject the least likely result of the first two, depending on the 
decision to be made. 
25/63 
8/63 
clinicians order a third test always and reject one out of three. 
clinicians sometimes or never order a third test and reject the least likely 
result most of the time. 
6/63 clinicians request third tests always or often and reject never, considering all 
values in their decision. 
Consultation with the laboratory in the case of divergent results is always or often 
done by 40 physicians. 
Fourteen clinicians sometimes consult the laboratory, taking into account the impor-
tance of the situation (2x). Nine never consult the laboratory, three of these (all 
working in the same hospital) declare explicitly that there is no use in taiking to the 
laboratory. 
6.2 .2. Speed of test versus reliability. 
When asked for which tests a semiquantitative test would be preferred over a quanti-
tative one, provided that the result would be avallable in a short tum-around time, 
clinicians mentioned the following constituents: 
glucose (29 times) CPK ( 4 times) 
Hb ( 9 times) Amylase ( 4 times) 
K (11 times) NH3 (4 times) 
creal. ( 9 times) Na (3 times) 
SGOT ( 9 times) eight constituents were named twice, 
SGPT ( 9 times) thirteen others once. 
Some clinicians who voiced their wish for faster results would not accept less accu-
racy (glucose (2x), K (5x), creatinine {2x), Hb and urea (!x)). 
Seventeen clinicians did not have special interest with regard to this question. Seven 
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of them reported stat-service to be adequate. Four explicitly stressed the impor-
tance of accuracy. 
6.2 .3. Molecular units 
Of the 12 hospital laboratories participating in this study 7 changed to molecular 
units in 1971 (39 clinicians), I in 1973 (4 clinicians) and I in 1974 (9 clinicians). 
One clinician changed to a hospital where molecular units were used in 1976 and 
thus started using these units in that year. 
The answers to the question how long it did take to get used to the new units were 
distributed as follows: 
period less than 3 months 3-12 months more than I year 
number of clinicians 15 20 17 
In three hospitals (18/52 clinicans) the change to the new units was reported by 
some clinicians ( 4/18) to have been planned well. As one interviewer put it: "like 
the change from left to right traffic in Sweden". 
In these three hospitals the answers were distributed as follows: 
period less than 3 months 3-12 months 
number of clinicians 10 7 
more than 1 year 
I 
As to the question whether molecular units enabled clinicians to give better treat-
ment to patients the answers were: 
better treatment yes somewhat no 
number of physicians 4 2 46 
The 4 clinicians answering positively to this question mentioned osmolarity (3 times) 
and electrolytes once. 
A larger number of clinicians gained more insight into biochemical processes while 
using molecular units: 
more insight yes somewhat no 
number of physicians 5 13 34 
Examples given by those who reported to have gained insight were: 
osmolarity (6x), "ions" (5x), relationship T ,-T 4 and relationship cholesterol-cholic 
acids (lx). 
A number of clinicians report to still convert mmol/1 into mg% before taking a 
medical decision: 
frequency always often sometimes never 
number of physicians I 4 19(11) 28(5) 
The numbers in brackets represent the numbers of physicians that report exceptions 
to their answer; thus, out of 4 7 clinicians answering to convert "sometimes" or "never" 
16 report to convert mmol/1 into mg% "'always" or "often" for one or more consti-
tuents. 
Particularly mentioned were: glucose (15x), urinary glucose (2x), urea (7x), calcium 
(4x), creatinine (2x), phosphate, Ca. P product, cholesterol and Hb once. 
Most physicians are still familiar with the weight per volume units, as becomes appa-
rent from the frequency of converting mg% into mmol/1 when these units are presen-
ted e.g. in the literature 
frequency 
number of clinicians 
6.3 Discussion 
always 
2 
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often 
5 
sometimes 
6 
never 
39 
6.3.1. Repeated testing and procedure followed in case of an unlikely 
result. 
Fifty two out of 63 clinicians always or often repeat a test before taking a medical 
decision. Half of them do so in particular when the first result is incompatible with 
their expectations or when the decision to be made is important. 
Repeat tests contribute considerably to increasing workloads in the clinical labora-
tory and to increasing costs of health care (8) and in this respect it is interesting to 
discuss the clinicians's habit to order repeat tests. 
It is the clinician's responsibility to the patient to repeat tests when results are 
incompatible with their expectations or when the decision to be made is important. 
To routinely repeat tests before making a decision may reflect the clinician's doubt 
about e.g. the dietary status of the patient, the technique of sample taking or the 
analytical reliability of the laboratory. 
In this study we described (section 5.2.3.) for which analyses clinicians reported to 
think laboratory performance unsatisfactory. We see some correlation between the 
number of tests per hospital for which dissatisfaction is expressed and the num-
ber of clinicians routinely repeating tests. In hospitals 5, 6, 8 and 10, 38-44% of 
clinicians routinely repeat tests before making a medical decision, while 2.1-4.5 
tests per clinician were named that need improvement (mean 3 .6). In the other 
Dutch hospitals: 4, 7, 9 and ll a dissatisfaction with analyses of0-3.5 (mean 2.2) 
per clinician is recorded and in these hospitals 25-33% of clinicians orders retests 
routinely. 
We note the fact that four large hospitals constitute the first group, while the second 
group represents smaller hospitals. In the hospitals in the United States and Canada 
3/4 and 2/3 clinicians report to routinely repeat tests, while they were most satisfied 
with the analytical performance of the laboratory of all. This incongruency may 
be due to a different general attitude in these countries towards laboratory results. 
In two out of four hospitals where dissatisfaction with laboratory results and 
frequency of repeat tests is high overall intralaboratory variability ranks* 8 and 9 out 
of 9 Dutch hospitals respectively and here intralaboratory variability may be respon-
sible for the clinicians' behaviour. In the two other hospitals intralaboratory variabil-
ity ranks l and 3 out of 9 respectively in the Dutch group. There must be another 
reason for the clinicians' relative dissatisfaction in these hospitals. 
*For each constituent the average coefficient of variation for both controlsera is calculated for 
each hospital. Hospitals are ranked according to average coefficient of variation. For each hospital 
ranknumbers for all constituents are summed and hospitals are ranked for overall intralaboratory 
precision according to these ranksums. 
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In both hospitals 4 out of 8 clinicians (50%) noted, that clerical errors, mix-up of 
samples etc. were a source of aggravation in response to question IV of the question-
naire as to needed improvement (section 5.2.3). Similar remarks were made by 
less than 30% of clinicians in 4 other hospitals. 
In one of the two hospitals 6/8 clinicians report to never consult the laboratory 
in case of an unlikely result. Three out of these six note that "there is no sense in 
talking to the laboratory". No similar remark was heard in any other hospital in 
this study. 
In conclusion, there is an indication that the clinicians feeling of satisfaction with 
laboratory performance results in a relative low repeat test rate. In 2/4 hospitals, 
where stated frequency of retesting is high intralaboratory variability is higb, in the 
two other hospitals bad communications and suspected clerical errors seem to be 
involved. It has been reported by Me Swiney and Woodrow (41) and by Grannis 
et al. (30) that clerical errors, mix-up of samples etc. may account for more than 
50% of the errors in the clinical chemistry laboratory. 
Ten clinicians out of the total of 63 report to seldom or never repeat a test. Their 
motivation for not doing so may range from relative heavy reliance on the clinical 
picture and/or a great confidence in the laboratory, to dispair, as one of the clini-
cians interviewed indicated: "there is no sense in repeating tests. The laboratory 
will tell you the second value is the same as the first anyhow". 
When upon repeated testing a value is reported that is considerably different from 
the first one 24 physicians choose - depending on the decision involved -between 
(a) reordering the test for a third time and (b) rejection of the result that is least 
likely in the given situation. A similar number of physicians (25) orders the test 
for a third time and rejects one out of the three results. Seventeen out of twenty-
five contact the laboratory in this situation. Four out of eigbt clinicians who reject 
the least likely result most of the time and retest never, do contact the laboratory. 
All six clinicians who always order a repeat test, but never reject, consult the labora-
tory. 
Motivations of clinicians to consult the laboratory were: (a) to be informed on 
possible blunders (mixup of samples, mistakes in calculations etc.) and (b) to inform 
the laboratory on the situation. Of those who said "sometimes or never to consult 
the laboratory", 3 did so only if it was an important case, 3 others reported that 
there was little use in communicating with the laboratory. 
6.3 .2. Speed of tests versus reliability. 
There is a high demand for fast semiquantitative results as compared to a more 
accurate result on longer terms for glucose (named 27 times). Two clinicians did 
state that they want fast and accurate results. Out of 19 clinicians who answered 
the question of desired accuracy by stating two values between which a distinction 
is to be made, eleven gave figures for glucose of I or 2 mmol/1 or 10-15% which 
constitutes about the difference the average laboratory can detect using a quanti-
tative procedure (median 3 CV in this study: 15% (table 3-1)). Six, more realistically, 
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mentioned differences of 4-10 mmol/1 or 30 - 50% at this question. Two more 
stated to be interested in the differential diagnosis of hyper- or hypoglycaemia. 
6.3 .3. Molecular units 
In 1970 the Dutch Association of Clinical Chemistry decided to recommend to its 
members the use of Sl units (5, 67), the system of units constructed by the Confe-
rence Generale de Poids et Mesures. The association adopted the proposal of the 
Subcommittee for Standardisation of Units in Clinical Chemistry of the International 
Federation for Clinical Chemistry (!FCC) to use molecular units where possible 
to record mass concentration in reports of analytical results in clinical chemistry. 
The majority of laboratory directors has responded positively to this recommenda. 
tion and molecular units have been in use for two to five years by 52 clinicians 
(9 hospitals) cooperating with this study. Since the decision as to the introduction 
of the SI-system with or without secondary agreements is presently being considered 
in many countries it is of interest how clinicians have responded to the new units 
(10) and to this purpose some questions on this subject have been added to the 
questionnaire. 
This study reveals, that 17 out of 52 clinicians needed more than a year to get used 
to the new units. Remarks such as: 'Til probably never learn" or "! am still not used 
to them" were heard from ! ! members of this group. A total of 2! clinicians still 
frequently convert for one or more constituents mmol/l into mg% before making a 
decision. There is some evidence that thorough preparation of the introduction 
of the new units leads to a decrease of the period of time needed to get adjusted. 
Seven out of 52 clinicians report to always or often convert mg% e.g. from the 
literature, into mmol/1 for optimal interpretation. 
A few clinicians have experienced advantage in the treatment of patients using 
the mmol. One clinician noted the advantage of molecular units in diabetic coma 
simultaneously with the impossibility of routine treatment of diabetes with these 
units. A diabetes specialist, familiar with the mmol from research studies, thought 
the same unit inconvenient in routine practice. 
It is interesting to note, that glucose was mentioned by 17 out of 52 clinicians as 
being a constituent for which they frequently convert mmol/1 into mg%. 
In conclusion, in the present state of the art, the molecular unit does not seem to 
contribute positively to medical treatment. In the case of glucose the objections 
to the molecular unit seem to be fundamental. 
With respect to the procedure of introduction of the new units at least two aspects 
are to be taken into account: 
There is a true mental inertia comparable to, for example, the lack of imme-
diate response of the individual, familiar with degrees Fahrenheit to a report of 
a patient running a fever of 40.5 degrees Celsius even if conversion factors are 
known. 
-- For a value or numerical figure to become familiar the absolute number is impor-
tant. 
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A remark relevant in this respect was "I have nothing against the mmol, but the 
old units were so much more convenient". 
It seems that the more decimal points are introduced, the less popular the figure will 
become. Unfortunately tlris is the case for many constituents when mg/% are con-
verted to mmol/1: 
calcium: 10.4 mg% 2.60 mmol/1 
glucose: 120 mg% 6.6 mmol/1 
urea: 30 mg% = 10.8 mmol/1 
cholesterol 
uric acid 
250 mg% 
9.0 mg% 
Basic didactic techniques are needed to overcome these difficulties. 
= 6.5 mmol/1 
= 0.53 mmol/1 
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Chapter VII 
INTERPRETATION OF LABORATORY RESULTS FROM ANOTHER HOSPITAL 
7 .I Introduction 
The answers to the following questions of the questionnaire will be presented in this 
chapter: 
VII Suppose a patient is referred to you while laboratory data have been deter-
mined in another laboratory than your own. How do you proceed? 
- you evaluate the results with the normal values you usually apply in mind 
yes/no 
- you ask for a repeat of all tests yes/no 
- you ask for a repeat of clinically relevant tests only yes/no 
- you relate the data to the normal values of the laboratory in question yes/no 
- if these normal values are not directly available do you inquire? yes/no 
Vllla Suppose a patient is referred to you from another hospital. In the table the 
laboratory value reported for this patient is given. You ask for a repeat test 
in your own laboratory and find the other value given in the table. Is there a 
change in the condition of the patient? yes/no 
b What would be your answer if the two values were results for one patient both 
determined in your own laboratory? yes/no 
Na K Cl Ca P urea ere at. glue. chol. !.prot. Hb 
mmol/1 j.Lmol/1 mmol/1 gr/1 mmol/1 
1st 136 3.5 108 2.40 0.95 3.3 82 3.5 4.5 73 8.8 
2nd 141 4.2 102 2.65 1.25 5.6 100 5.5 6.1 68 7.8 
7.2 Results 
With regard to laboratory results from another hospital clinicians report to act as 
follows: 
25/63 repeat clinically relevant tests after relating the results to the normal values of 
the other hospital. 
16/63 repeat cllnically relevant tests after relating the first results to the normal 
range of the own laboratory (e.g. electrolytes) and to the normal range of the 
other laboratory (particularly for enzymes). 
8/16 say to repeat only abnormal or unexpected values. 
13/63 consider the result with own normal values and the other laboratory's values 
in mind, but repeat all tests. 
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7/63 do not pay much attention to the reported result but repeat all tests or clini-
cally relevant tests. 
2/63 assume the differences between laboratories to be negligible. 
Out of the total of 63 clinicians 8 say that they accept the other laboratory's results 
particularly if the hospital laboratory is known. 
If the normal values of the other laboratory are not known 18/63 declare to seek this 
information. Ten more clinicians do so only if the situation is acute or important, if 
there is doubt, if it concerns enzymes or hormones, or if a repeat test is difficult. 
In table 7-1 clinicians answers are given to the question if two successive values for 
one patient given in the table, represent a change in the condition of the patient if 
(a) the first value was determined in another laboratory and the second one in the 
own laboratory and (b) if both values were determined in the own hospital labora-
tory. The two values were chosen to represent successive results for the same patient 
in the normal range differing about 16 of the range of normal values. In chapter V 
we discussed which change in an individual patient clinicians would consider signif-
icant when given a starting value in the near abnormal range. From the frequency 
distributions of their answers (figure 5-l) we can deduce how many clinicians would 
consider the change given in this chapter a significant change in the near abnormal 
range. In the last column of table 7 wl these numbers of clinicians are given. 
In table 7w2 a comparison is made between intralaboratory variability and interw 
laboratory variability. The latter is derived by calculating the dispersion ( coeffi-
cient of variation, CV) of the first values of the ten determinations each laboratory 
carried out for the controlsera. 
Nawmmol/1 
K-mmol/1 
Cl-mmol/1 
Ca-mmol/1 
P-mmol/1 
urea-mmol/1 
creat.-,umol/1 
gluc.-mmol/1 
chol.-mmol/1 
t.prot.-gr/1 
Hb-mmol/1 
fust 
value 
136 
3.5 
108 
2.40 
0.95 
3.3 
82 
3.5 
4.5 
73 
8.8 
second 
value 
141 
4.2 
102 
2.65 
1.25 
5.6 
100 
5.5 
6.1 
68 
7.8 
difference 
5 
0.7 
6 
0.25 
0.30 
2.3 
18 
2.0 
1.6 
5 
1.0 
2 3 4 
number of clinicians considering this difference a 
change in the condition of the patient if: 
1st value other lab. 
2nd value own lab. both own lab. both own lab. 
(normal range) (normal range) (near AN 
range) 
2 10 39 
24 35 63 
I 10 46 
29 41 58 
15 19 33 
9 21 22 
15 19 22 
9 16 32 
19 27 54 
3 5 13 
35 43 54 
Table 7-1: Nwnbers of clinicians considering a change in constituent level in a patient as given 
in column 1 indicative of a change in the condition of the patient if: 
- the first value was determined in another laboratory and the second one in the 
own hospital laboratory (column 2) 
-both values were determined in the own laboratory (column 3) 
- the change as given in column 1 took place in the near abnormal (AN) range 
(column 3). These data are derived from figure 5-1. 
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The ratio between interlaboratory variability and median intralaboratory variability 
is given as well as the number of laboratories where intralaboratory variability 
exceeds observed interlaboratory variability on this occasion. 
7.3 Discussion 
Few clinicians accept results from other hospitals as such. The majority repeats 
clinically relevant tests or abnormal tests only. It can be noted that in the latter case 
the non-aberrant result is accepted tacitly. A considerable number of clinicians 
(20/63) repeats all results no matter what. 
The greater confidence of clinicians in their own laboratory as compared to another 
laboratory also appears from table 7-1. Given two hypothetical values for the same 
patient a change in the condition of the patient is concluded more often if both 
detenninations were carried out in the own hospital laboratory as compared the 
situation where the first determination was reported by another laboratory and 
the second by the own laboratory. 
In either situation changes for K (3.5-4.2 mmol/1), Ca (2.40-2.65 mmol/1), Hb 
(8.8-7.8 mmol/1) and cholesterol (4.5-6.1 mmol/1) are considered representative of 
a change in the condition of the patient most frequently, changes for glucose (3.5-
5.5 mmol/1), creatinine (82-100 !lfllol/1), urea (3.3-5.6 mmol/1) and P (0.95-1.25 
mmol/1) in less cases. A change in total protein level of 73-68 gr/1, of Cl of 108-102 
mmol/1 and of Na of 136-141 mmol/1 is considered significant by few clinicians 
only. 
While the values were chosen essentially in the normal range (table 7-1 column 1), 
it could not be avoided that for a number of clinicians one of the values was near 
their personal action level for that constituent. This was particularly the case for 
K, Ca and Hb. When comparing the data of this chapter with those of chapter V on 
a medically significant change in a patient In the near abnormal range (figure 7-1, 
column 4) we see that for all but two constituents (urea and creatinine) the same 
change in a patient is considered significant by more clinicians if the starting value 
approaches the near abnormal range as compared to the normal range. 
In summary, firstly, a change of about )6 of the normal range in an individual patient 
has - clinically - a different meaning for each constituent. Secondly, the same 
change for a particular constituent level is differently interpreted if it occurs in a 
different concentration range. In the near abnormal range clinicians tend to be 
more strict than in the normal range. 
It is generally assumed that reproducibility within the laboratory is 3 to 4 times 
better than reproducibility between laboratories (29, 52). We do not find this to 
be true in every case and confirm in this study the recent data of Gilbert (26) who 
states on the basis of data of the College of American Pathologists Survey Program, 
that 2/3 to 3/4 of analytical errors are caused by factors within the laboratory. 
In this study each laboratory tested the controlsera ten times. If we compare the 
median intralaboratory variability in these ten results with the variability in the 
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intralab. interlab. ratio number of labs. with 
var. (CV) var. (CV) inter/intra intralab. var. equal to or 
lab. var. exceeding interlab. var. 
Na I 0.9 (0.3-1.4) 1.8 2.0 0 
ll 1.2 (0.7-2.1) 2.1 1.8 1 
K I 1.2 (0.5-2.3) 2.7 2.3 0 
ll 2.0 (1.1-3.7) 2.8 1.4 1 
C1 I 1.4 (0.4-2.0) 1.6 1.1 4 
II 1.4 (0.7-2.4) 1.6 1.1 5 
Ca I 1.8 (0.9-2.6) 3.8 2.1 0 
II 1.8 (1.0-4.0) 2.5 1.4 4 
p I 2.9 (1.5-8.3) 4.3 1.5 4 
II 2.7 (1.5-5.6) 7.1 2.9 0 
urea I 3.1 (1.1-8.7) 11.0 3.5 0 
II 2.8 (0.9-7.9) 6.2 2.2 1 
creat. I 3.I (1.2-7.1) 6.1 2.0 1 
II 2.7 (1.2-7.4) 6.2 2.3 1 
glue. I 5.0 (2.2-7.1) 12.8 2.6 0 
II 4.8 (2.3-6.3) 9.0 1.9 0 
chol. I 3.4 (1.7-5.1) 7.5 2.2 0 
II 3.8 (2.0-5.7) 7.3 1.9 0 
t.prot. I 2.3 (0.9-4.3) 2.5 1.1 6 
II 2.2 (1.3-4.2) 3.4 15 2 
ALP I 5.1 (3.1-14) 33 6.5 0 
ll 4.2 (1.2-12) 38 9.0 0 
LDH I 7.1 (3.0-12) 25 3.5 0 
II 4.6 (1.3-12) 28 6.1 0 
Hb I 1.9 (1.2-3.7) 3.3 1.7 2 
II 1.9 (0.9-3.7) 2.3 1.2 3 
Table 7.2: Intralaboratory variability related to interlaboratory variability. 
first reported results for each controlserum by each laboratory (table 7-2) we see 
that intralaboratory variability is in general 1.1-3 .6 (mean 1.9) times larger than 
median intralaboratory variability. Exceptions are the enzyme determinations, 
where interlaboratory variability ic 3.5-8.6 times larger than the variability within 
the average laboratory. This stresses the need for the development of a means of 
communication between hospitals for these determinations in particular (see Chapter 
Ill, section 3 .3 .1 ). 
As mentioned in chapter III intralaboratory variability when studied in the way it 
was done in this study is, if anything, more likely to be smaller than larger than true 
intralaboratory variability. Yet, for all constituents, except glucose, cholesterol and 
the enzymes there is a number of laboratories that exhibit in tills survey an intra-
laboratory variability exceeding the variation between hospitals (Fig. 7-2, last column). 
In other words, based on thls particular set of data, clinicians in these hospitals have 
no reason to rely more on results from their own laboratory as compared to results 
from other hospitals in this group. 
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Chapter VIII 
SUMMARY AND CONCLUSIONS 
The main question leading to the work described in this thesis is: how accurate 
and how precise do measurements in clinical chemistry have to be to provide good 
service to the clinic. 
In clinical chemistry required precision and accuracy, or rather allowable variability 
is hard to establish. Firstly the determinations (inclusive sample taking) have seldom 
been performed with a variability so small that it did not interfere with the biological 
variations to be measured. Secondly, medical decision making is a process of pattern 
recognition in which the laboratory result plays an important role in some cases 
and a minor one in others. 
A project was set up to study the present situation: how do physicians use laboratory 
results, does analytical variability affect medical decision making and in particular, 
for which determinations is - from the clinical point of view - analytical perfor-
mance good, adequate or eligible for improvement respectively. 
A questionnaire was designed ci.nd submitted to 63 senior specialists in internal 
medicine, working in teaching hospitals. 
The questionnaire focussed on the following subjects: 
normal range values and action levels (action level being defined as a constituent 
level that prompts the clinician to an action of the first order i.e. repeated or 
additional laboratory tests, ECG, X-ray, or change in diet or medication) 
- medically significant change in the individual patient 
- possible sources of variation in test results 
satisfaction with laboratory performance 
a number of other relevant subjects such as: repeated testing, speed of testing 
versus reliability of the result, the use of molecular units and the interpretation 
oflaboratory results from other hospital laboratories. 
The interviews were held in person and lasted 30-45 minutes. 
Concurrently the laboratories serving the participating clinicians analysed samples 
of quality control sera in order to collect information as to intra. and interlaboratory 
variability. Also, normal range values were reported by the laboratory. 
In the addendum to this thesis a form for reporting in interlaboratory surveys, 
giving simultaneously information on intra· and interlaboratory variability, is de~ 
scribed. 
The determinations under study were: sodium, potassium, chloride, calcium, inorganic 
phosphorous, urea, creatinine, glucose, cholesterol, total protein, alkaline phospha· 
lase, lactate dehydrogenase and hemoglobin. 
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Laboratory survey 
The results of the laboratory survey were processed in order to be usefull in the 
interpretation of clinicians' answers to the questionnaire. 
Day to day variability was determined for each laboratory. Significant differences in 
intralaboratory variability between hospitals were found for all constituents except 
for sodium, chloride, glucose and cholesterol. 
Systematic analytical bias between laboratories was not found to be consistently 
reflected in the range of normal values given by the laboratory director. In only 16 
out of 35 cases of most evident systematic bias with respect to the group oflabora-
tories did the normal range show the same tendency. Consequently, while it is 
common practice to use the normal range as a point of reference in interhospital 
communications, this habit finds no justification in this study. 
Differences in the population tested for determination of the normal range could 
in some cases be related to differences in normal range values (outpatients versus 
blooddonors or hospital personel, age differences). 
It was noted that protocols for determination of the normal range differ considerably 
in the group of hospitals cooperating with this study. 
Requirements for analytical performance from the clinical point of view. 
In order to derive clinical requirements for analytical performance with respect 
to day-to-day precision from the data collected in this study three criteria have 
been used: 
- the difference between either limit of normal and the respective action level 
the change of constituent level in the individual patient, given a certain initial 
value in the near abnormal range, that is considered medically significant 
clinicians satisfaction and dissatisfaction respectively with test results 
Previous attempts described in the literature to derive requirements for analytical 
performance have been predominantly based on the concept, that analytical varia-
bility should not exceed biological variability, either between or within individuals. 
However, to base analytical requirements on biological variation between individuals 
(the normal range) does not seem to respond to the practical situation: 
in clinical diagnosis it is the difference between the population in health and the 
population in disease that counts. Upper and lower limits of normal are different 
entities in this respect and the width of the normal range is irrelevant in this 
situation. 
in the follow-up of the individual patient the variation between individuals is 
irrelevant. 
in our study it was found, that a change in an individual of about ~of the normal 
range is considered significant for some constituents but much less for others 
(chapter VII). 
also, in our study clinicians tend to be more strict in the upper decision range as 
compared to the lower decision range for a number of constituents, for example 
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for potassium, calcium, creatinine and the enzymes, the opposite is true for 
inorganic phosphorous (chapter IV). 
Biological variation within the individual is a useful! basis for analytical require-
ments in screening projects in preventive medicine. For daily practice hvwever, 
this approach does not seem realistic for the following reasons: 
in the most common situation of wanting to distinguish the diseased patient from 
the healthy population the intraindividual variation does not play a role 
the intraindividual variability has hitherto been determined in healthy individuals. 
ln practice we seldom follow up the healthy individual and intraindividual varia-
tion is likely to change in disease. In our study a certain change in constituent 
level was interpreted differently when the change took place in the normal range, 
or in the near abnormal range. (chapter V and Vll). 
Consequently neither approach is complete. In our attempt to establish requirements 
for analytical performance from the clinical point of view we have considered the 
two situations of a. to distinguish the patient from the healthy population and b. to 
follow up the individual patient. 
The main difficulty encountered was related to the large discrepancies of clinicians' 
answers. 
The dispersion of answers to the question of a significant change in a patient was of 
the same order of magnitude as intralaboratory variability. The discrepancies in 
clinicians' action levels were much larger, differences among clinicians of one hospital 
often being as large as differences among clinicians of different hospitals. Often 
action levels in the upper and lower decision range did overlap. Although several 
good reasons can be named why criteria for taking action may vary a discussion 
Another factor that should be taken into account upon interpretation of the data 
was that 31/63 clinicians referred to the normal range given by the laboratory 
when asked for normal values. While determining for these clinicians the differences 
between limits of normal and respective action level the laboratory's limits of normal 
were used for calculations. 
In general (except for inorg. P) the median difference between limit of normal and 
action level was smaller than the average medically significant change in the individ-
ual patient. As the initial values for the latter were all in the near abnormal (AN) range, 
we conclude that the decision range between normal and abnormal is the most 
critical one where analytical reliability is most needed. 
This is also shown in the following table summarizing the data from chapter IV and 
V on requirements for laboratory performance from the clinical point of view: 
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decision range near AN range clinicians' opinion 
(median difference (medically sig- (improve-
limit of normal nificant change ment needed) 
and action level) in a patient) 
analytical precision 
is adequate for: K, P, urea Na, K, urea, 
chol. creal, 
t. prot., ALP, 
LDH,Hb 
is just short of good 
performance for: Na,Cl Cl, P, glue, 
is eligible for 
improvement for: Ca, creal, glue. Ca Ca, creat. 
chol, t. prot., t. prot., Hb, 
ALP,LDH,Hb "enzymes" 
Evidently, improvement of the precision of calcium determinations is a must. 
In the decision range improvement of laboratory performance is also indicated for 
creatinine, glucose, cholesterol, total protein, alk. P-ase, LDH and hemoglobin. This 
finding largely correlates to the fact that for all but two of these constituents signif-
icant numbers of physicians are dissatisfied with test results. This indicates, that the 
proposed model of deriving criteria for analytical performance from the difference 
between limit of normal and action level - however limited by the dispersion of 
answers - is a sensible approach. 
For glucose and cholesterol clinicians did not feel improvement oflaboratory perfor-
mance was needed, while according to our data analytical performance was less than 
adequate in the decision range. Appreciable numbers of clinicians assumed for these 
constituents biological variations to be the main cause of day to day variations in 
laboratory results. Probably laboratory variability plays a larger role than presently 
assumed and improvement of laboratory performance for these constituents may 
open new horizons. 
We have considered median intralaboratory variability and have to remember, that 
half of the laboratories perform better than reported here, and the other half per-
forms worse. In some cases differences in precision were registered by clinicians. In 
hospitals where laboratories have larger intralaboratory variability they may apply 
a wider range as medically significant or more clinicians may be dissatisfied with 
determinations as compared to clinicians working with more precise laboratories. 
This situation has been shown for potassium, calcium, creatinine and inorg. phos-
phorous. It may be relevant, that no such relationships could be demonstrated for 
total protein, hemoglobin and the enzymes, while considerable numbers of physicians 
voiced dissatisfaction. Other factors i.C. technique of sample taking or patient prepa-
ration may be involved. 
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Thus having indicated for which constituents improvement of day to day precision 
in the laboratory is needed table 8-1 shows the desirable degree of precision based 
on our data compared to those of a number of other studies: Barnett (4), Campbell 
and Owen (9), Gilbert (27), Cotlove eta!. (14) and Steele c.s. (58). 
The average medically significant change in a patient in our study is closest to the 
medically significant values given by Gilbert. 
When we consider the conclusions of the study of Steele e.a. (58) evaluating labora-
tory performance against criteria based on intraindividual variation according to 
Cotlove and coworkers (14) we find that laboratory performance for sodium and 
chloride needs to be improved as urgently as that for calcium. This is hard to believe 
from the point of view of the practicing physician. 
The most strict requirements for most constituents are those based on median 
difference between limit of normal and action level derived from our study. Although 
hard to meet it is our conviction that these values should be our targets in order to 
meet present medical needs. They correlate largely with physicians' satisfaction. 
This is however, not to say, that patient care will automatically improve if lab ora· 
tories improve their performance to meet these targets. 
Other aspects are equally important for example: a discussion of physicians among 
themselves on the subject of medical significance of laboratory results, a discussion 
among laboratories and physicians on normal or reference values, standardization of 
the technique of sample taking and the design of a means of communicating levels of 
precision - and changes thereof- to the clinician. 
Repeat testing 
As to the attitude towards repeat testing it was found that the majority of clinicians 
(52/62) always or often repeats a test before making a medical decision. Half of them 
declare to do so in particular when the first result is incompatible with their expecta-
tions or when the decision to be made is important. Evidence is found, that in the 
four large hospitals in Holland where the rate of routinely repeat testing is high 
as compared to the other Dutch hospitals the number of tests per clinician for which 
greater reliability is desired is comparibly high as well. In 2 out of these 4 hospitals 
overall intralaboratory variability is high, in the other two hospitals bad communi-
cations and clerical errors came up during the interview most frequently of all hospi-
tals. 
Fast semiquantitative tests. 
Fast semiquantitative results as compared to a more accurate result on longer terms 
was desired in particular for glucose (27/63 clinicians). When asked for desired 
precision 11/19 gave figures obtainable with quantitative methods only. 
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Requirements for analytical precision (3 SD) based on: 
Medically significant difference lntraindividual variability 
2 3 4 5 6 7 
near AN range 
decision range indiv. patient Barnett (4) Campbell (9) Gilbert (27) Cotlove (14) Steele (58) 
Na-mmol/1 3.0 5.1 6 7 4.5 1.5 0 
K-mmol/1 0.3 0.38 0.75 0.61 0.45 0.42 0.54 
Cl-mmol/1 4 5.2 6 8.6 4.5 2.7 2.6 
Ca-mmol/1 0 (0.01) 0.13 0.18 0.11 0.12 0.12 0.12 
P-mmol/1 0.10 0.25 0.24 0.13 0.18 0.21 0.27 
urea-mmol/1 1.3 2.46 2.1 1.6 2.1 3.2 1.9 
creat.-,umol/1 0 (1) 29.9 27 15 
gluc.-mmotr 0 (0.1) 2.17 0.84 0.43 0.51 0.75 0.42 
chol.-mmol/1 0 (0.1) 1.33 1.56 1.17 1.32 1.02 
t.prot.-gr/1 2 6.9 9 6 6.3 5.4 
ALP-% 0 18 
LDH-% 10 22 27 
Hb-mmol/1 0(0.1) 0.75 0.93 
Table 8-1: Comparison of criteria for analytical performance derived from different studies, expressed as 3 SD. 
(If analytical variability is 1 SD we may consider a difference of 3 SD to be discernable- see text-). 
The data in column 1 through 5 represent medically significant differences, i.e. differences between 
two values between which the physician wants to distinguish. Data in column 1, derived from the 
present study are based on median difference between limit of normal and action level in the most 
critical decision range (for details see table 4-4). In cases where median difference is zero the smallest 
difference recognizable, given the number of decimal points, is placed in parentheses. The data in 
column 2 represent the average medically significant change in a patient (improvement) starting from 
an initial value in the near abnormal range (table 5-2). 
Data in column 3, 4 and 5 represent "medically significant values", "acceptable analytical limits" 
and "analytical goals" in the normal/decision range, expressed as 3 SD, as given by Barnett (4), Camp-
bell and Owen (9) and Gilbert (27) respectively. 
The criteria for analytical performance in column 6 and 7 are based on intraindividual variability 
determined by Cotlove et. al. (14) and Steele et. al. (58). 
The use of molecular units. 
Molecular units do not seem to contribute positively to medical treatment. In the 
case of glucose the objections to the molecular unit seem to be fundamental. 
Difficulties to be encountered with introduction of the new units should not be 
underestimated. 
Seventeen out of 52 clinicians stated to have needed in ore than a year to get adjusted 
to the new units and 20/52 reported to after 2-5 years still always or often convert 
mmol/1 into mg% for one or more constituents for optimal interpretation. 
Laboratory data from another hospital laboratory. 
Few clinicians accept results from other hospitals as such. 
The same change of constituent level in a patient is considered a change in the condi· 
lion of the patient by 2-12 (average 7.6)more clinicians if both determinations were 
carried out in the own hospital laboratory as compared to the situation where the 
first result was determined in another laboratory and the second one in the own labo· 
ratory. 
In our study the average ratio of interlaboratory variability to intralaboratory varia· 
bility is 1.9 to I (range 1.1-3.6 to 1), excluding the enzymes. We conclude, that 
intralaboratory variability plays an important role in generating differences between 
laboratories and hence efforts in quality control should emphasize this aspect. 
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SAMENVATTING 
De vraag die geleid heeft tot het werk dat in dit proefschrift beschreven wordt luidt: 
hoe nauwkeurig, met name hoe reproduceerbaar, moeten klinisch chemische bepa-
lingen zijn om bij te kunnen dragen tot een goede behandeling van de patient. 
Het beantwoorden van deze vraag is niet eenvoudig. Enerzijds is de spreiding van 
dag-tot-dag van laboratoriumuitslagen, waarbij ook andere factoren zoals monster-
name een rol spelen, zelden verwaarloosbaar ten opzichte van de biologische verschil-
len die men wenst aan te tonen. Anderzijds is de laboratoriumuitslag slechts een van 
de vele gegevens, aan de hand waarvan de arts zijn diagnose stelt. De opzet van het 
onderzoek was na te gaan op welke wijze de arts laboratorium gegevens bij zijn 
besluitvonning verwerkt en of deze besluitvonning wordt beinvloed door de dag-tot-
dag spreiding van de laboratorium bepaling. 
In het bijzonder werd gepoogd een antwoord te vinden op de vraag voor welke bepa-
lingen - vanuit klinisch oogpunt bekeken - de nauwkeurigheid van het laboratorium 
goed, voldoende, dan wei voor verbetering vatbaar is. 
Aan 63 internisten in 12 ziekenhuizen met een interne A opleiding, academische 
en algemene ziekenhuizen, werden vragen voorgelegd over de volgende onderwerpen: 
normale waarden en laboratorium uitslagen die aanleiding geven tot het nemen 
van actie (actiewaarden). Onder actie wordt hierbij verstaan het aanvragen van 
herhaald of aanvullend laboratorium onderzoek, ECG, rontgen onderzoek, veran-
dering van dieet ofmedicatie. 
- een klinisch significante veranderiug van de bloedspiegei van een bepaald hestand-
dee! bij een patient. 
- tevredenheid respectieveliJk ontevredenheid met de nauwkeurigheid van het labo-
ratorium. 
voorts: het aanvragen van een herhaling van een test, voorkeur voor een snel 
semiquantitatief resultaat hoven een nauwkeurige uitslag op langere tennijn, 
moleculaire eenheden, interpretatie van uitslagen van laboratorium van een ander 
ziekenhuis. 
De laboratoria van de betreffende ziekenhuizen bepaalden monsters van kwaliteits 
controle sera. Op deze wijze werden gegevens verkregen omtrent de dag~tot~dag 
spreiding van resultaten binnen ieder laboratorium en omtrent de spreiding van 
resultaten tussen de verschillende laboratoria. 
Door ieder laboratorium werden de gangbare nonnale waarden opgegeven met 
eventuele bijzonderheden. 
Bij het bewerken van de gegevens over de spreiding binnen een laboratorium en over 
die tussen laboratoria werd gebruik gemaakt van een speciale wijze van rapporteren 
die in een addendum van dit proefschrift beschreven is. 
De bepalingen die bij dit onderzoek betrokken waren zijn: natrium, kalium, chloride, 
calcium, anorganisch phosphaat, ureum, kreatinine, glucose, cholesterol, totaal 
eiwit, alkalische phosphatase, melkzuur dehydrogenase en hemoglobine. 
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V ergelijkend laboratorium onderzoek 
Uit het vergelijkend laboratorium onderzoek konden de volgende conclusies worden 
getrokken in het Iicht van de vragen die aan de intemisten gesteld werden: 
- dag-tot-dag spreiding binnen een laboratorium verschilde statistisch significant 
voor aile bepalingen behalve voor natrium, chloride, glucose en cholesterol. 
systematische analytische verschillen tussen laboratoria werden niet steeds weer· 
spiegeld in de normale waarden van de betreffende laboratoria. 
de samenstelling van de groep normale personen, die gekozen werd door de deelne-
mende laboratoria ten behoeve van het bepalen van normale waarden, verschilde 
sterk van laboratorium tot laboratorium. 
Welke eisen stelt de kliniek aan de nauwkeurigheid van het laboratorium 
Door Tonks en anderen is gesteld dat de analytische spreiding van een klinisch che-
mische bepaling niet grater mag zijn dan een bepaald percentage van de biologische 
spreiding. Zoals ook uit dit onderzoek blijkt is deze benadering vanuit klinisch 
oogpunt niet relevant. 
In dit onderzoek zijn drie criteria gebruikt om vast te stellen voor welke bepalingen 
een laboratorium aan de eisen van de kliniek voldoet. 
- het verschil tussen hoven- of ondergrens van het normale gebied en de betreffende 
actiewaarde. 
die verandering van de bloedspiegel van een bepaald bestanddeel in een patient 
welke de arts als klinisch significant beschouwt. 
tevredenheid respectievelijk ontevredenheid met de nauwkeurigheid van het eigen 
laboratorium. 
Ondanks de aanzienlijke spreiding in antwoorden van de intemisten die geinterviewd 
werden konden een aantal conclusies getrokken worden. 
Aan de verbetering van de nauwkeurigheid van de bepaling van calcium dient grate 
aandacht te worden geschonken. In het kritieke gebied tussen normaal en juist abnor-
maal is ook de nauwkeurigheid van de volgende bepalingen, beoordeeld volgens de 
twee eerste hierbovengenoemde criteria onvoldoende: kreatinine, glucose, cholesterol, 
totaal eiwit, alkalische phosphatase, melkzuur dehydrogenase en hemoglobine. 
Voor deze bepalingen uitten de ondervraagden dan ook het meest frequent hun 
ontevredenheid, echter met uitzondering van glucose en cholesterol. Waarschijnlijk 
is de arts geneigd variaties in laboratorium uitslagen voor deze twee bestanddelen toe 
te schrijven aan physiologische schommelingen onder invloed van bijv. dieet en niet 
aan het te kart schieten van het laboratorium. 
In sommige gevallen kon een relatie gevonden worden tussen de mate van dag.tot·dag 
spreiding van de bepaling en die gemiddelde bloedspiegel verandering bij een patient, 
welke door de intemisten van dat ziekenhuis als wezenlijk werden ervaren. In andere 
gevallen bleek een relatie te bestaan tussen de mate van dag-tot-dag spreiding van de 
bepaling en de mate van tevredenheid van de internisten. 
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Voor totaal eiwit, hemoglobine en de enzymen konden dergelijke relaties niet aan-
getoond worden, hoewel relatief veel internisten ontevreden waren met de graad van 
nauwkeurigheid van deze bepalingen. Aanleiding tot de ontevredenheid over deze 
bepalingen zijn waarschijnlijk verschillen in monstemame techniek of niet herkende 
physiologische schommelingen. 
Het dient te worden opgemerkt, dat de behandeling van patienten niet zonder meer 
zal verbeteren wanneer het laboratorium aan de nauwkeurigheidseisen, zeals die hier 
gesteld zijn, voldoet. Andere factoren zijn hierbij eveneens belangrijk, zeals, discussie 
van artsen onderling over de vraag hoe medische besluitvonning op grond van labora-
torium uitslagen tot stand komt, een discussie van artsen en hoofden van lab aratoria 
over de te volgen procedure bij het vaststellen van normale of referentie waarden, 
standaardisatie van monstemame techniek, en het ontwerpen van een wijze van 
communicatie om de mate van reproduceerbaarheid - en wijzigingen daarvan -
door te geven aan de kliniek. 
Overige resultaten 
Uit de antwoorden op de resterende vragen van de vragenlijst kan nog het volgende 
worden opgemaakt: 
- in twee van de 4 ziekenhuizen, waar dikwijls herhalingen van laboratoriurn tests 
worden aangevraagd was de spreiding van de bepalingen in het algemeen groat, 
in de twee andere ziekenhuizen werden slechts communicatie met het labora-
torium en administratieve fouten meer dan in enig ander ziekenhuis genoemd. 
moleculaire eenheden dragen in de huidige situatie niet in belangrijke mate bij 
tot betere behandeling van patienten of beter begrip van biochemische proces-
sen. De practische problemen bij de invoering van deze eenheden mogen niet 
onderschat worden. 
In het algemeen hechtten de ondervraagden meer waarde aan laboratoriurn uitsla-
gen bepaald in het eigen laboratorium dan aan die bepaald in een ander labora-
toriurn. Uit het vergelijkend laboratorium onderzoek bleek echter, dat de sprei-
ding binnen een laboratorium in veel gevallen niet onaanzienlijk is ten opzichte 
van die tussen de laboratoria. 
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Quality Control in Clinical Chemistry 
The Two-sample Plot and Improvement of Laboratory Performance 
Elion-Gerritzen, Wiwka E.: Quality control in clinical 
chemistry. The two-sample plot and improvement of labora-
tory performance. Am J Clin Pathol 67: 91-96, 1977. 
A two-sample plot is often used to display test results in 
clinical chemistry external quality control programs. The use 
of control materials at different concentrations calls for a 
re-evaluation of the two-sample plot. A modification of the 
two-sample plot is presented. The axes of the graph are 
graduated in units of measurement rather than standard 
deviation intervals. The mean of all laboratories or a 
reference laboratory's value is entered as the target value. 
For each laboratory, repeated results for the same or similar 
control materials are recorded. Visual inspection of the graph 
gives immediate information as to the extent of intra-
laboratory variability, the incidence of systematic errors in 
the laboratory, and the size and type of systematic errors 
(proportional or constant) with respect to the target value. 
(Key words: External quality control; Internal quality 
control; Youden-Tonks plot; Two-sample plot; Random 
error; Systematic error; Proportional systematic error; 
Constant systematic error.) 
IN MANY external quality control programs or 
surveys in clinical chemistry where two control 
samples are distributed among participants, the two-
sample plot as described by Skendzel and YoudenHl 
or one of its modifications, e.g., the one suggested 
by Tonks, 12 is used to display test results. Skendzel 
and Youden point out that the graph displays the 
results from each participating laboratory and provides 
an opportunity for the appraisal of each laboratory's 
petformance: ''values, consistently high or low suggest 
a systematic error due to an improperly calibrated 
instrument, incorrect standard curve, deteriorating 
reagents or the laboratory's own modification of the 
recommended procedure. Points near the diagonal line 
through the median indicate that the laboratory is 
consistent. Pl<ltted points in other sections of the 
Received August 11, 1975; received revised manuscript February 
9, 1976; accepted for publication February 9, 1976. 
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graph represent values which do not follow a con-
sistent pattern and are attributable to random error, 
due to improper technic, mix-up of samples, or a 
clinical mistake." 
While Skendze\ and Youden10 do not specify concen-
trations of control materials, it is presently assumed 
that more information on laboratory petformance can 
be derived from the graph if the samples contain 
constituents in different concentrations. 1•11 
ThiS paper reconsiders the interpretation of the 
Youden- Tonks graph and presents a modified two-
sample plot that can help identify systematic errors. 
The Youden-Tonks Graph: Construction and 
Interpretation 
Let us consider an external quality control program 
where two control samples are being tested. Unless 
otherwise stated, it is assumed in this discussion that 
laboratories test the samples once, in the same run. 
Figure 1 represents a Yo1,1den-Tonks graph; the target 
value ( +) usually is defined as the coincidence 
point of the mean values of all laboratories for both 
control sera. On.each·axis equal distances are allotted 
to the I standard deviation (SD) values; the 1 and 2 
SD values represent the measure of dispersion of 
results for ali participant values for each control 
material. According to Skendzel, Youden, and Tonks 
the 45-degree diagonal line is drawn to allow partici-
pants in the program to appraise their perfonnance. 
Random Errors 
It is relevant to quote here the definition of random 
error as given in Webster's dictionary: 14 a statistical 
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+250 0---1 I : ____ j M 
-250 
I 
L--~-~-~---
-250 M +250 
serum I 
Fm. J. Two-sample plot as suggested by Skendzel and Youden. 
modified by Tonks. 
error that is wholly due to chance and does not recur-
opposed to systematic error. Random errors due to 
unpredictable variability in the laboratory (e.g., varia-
tion in sample or reagent volume) and blunders 
(e.g., mix-up of samples) are not likely to affect 
both samples in the same way, and the resulting 
coincidence point will deviate from the diagonal line in 
the Youden-tonks graph. 
Systematic Errors 
A systematic error is a statistical error· that per-
sists and cannot be considered as due entirely to 
chance-opposed to random errorY It is our ex-
perience fhat systematic errors can cause plotted 
points to deviate from the diagonal line in the Youden-
Tonks graph. This is particularly the case when control 
materials contain constituents at different concentra-
tions. 
Systematic Errors in the Laboratory 
We consider a laboratory using a nonlinear proce-
dure in the sense of less response at high absorbance 
values, or not sufficiently standardized in the abnormal 
range. When testing two control sera, one at a low-
normal (N) level and one at a high-abnormal (AN) level, 
this laboratory will report a low value for the high-
abnormal serum, and the plotted point will show up 
as a previously mentioned random error in the Youden-
Tonks graph. On repeated testing the coincidence 
point of this laboratory will always show up under 
the diagonal line. We have seen an example of this 
situation in the lind Eurotransplant Clinical Chemistry 
Survey.4 Figure 2 shows the Youden- Tonks graph 
for urea; laboratories tested both controls twice, in 
duplicate. In response to a questionnaire, laboratories 
A-F reported to standardize in the normal range only. 
Another example of a systematic error in the labora-
tory that causes the coincidence point to deviate from 
the diagonal line is given in Figure 3. Laboratory G 
tested two control sera (1974 pools of the Massachu-
setts Society of Pathologists Quality Control Program, 
MSPQCP)1 on four different days for cholesterol. G is 
the mean value; the dots represent the individual 
results. Repeatedly a too-high value for serum II was 
found. Most likely the high bilirubin level in serum 
II systematically interfered with this cholesterol proce-
dure, which did not ca!l for a sample blank. 
The systematic errors described here are persistent; 
they are predictable and avoidable once the cause is 
known. 
Proportional and constant systematic errors 
When control materials in the same concentration 
range are distributed, incorrect standardization or dif-
ferences in methodology between laboratories will 
result in values higher or lower to the same extent 
for both samples. The coincidence point will be located 
along the diagonal line of the Youden- Tonks graph. 
When control materials contain constituents in differ-
ent concentrations it is important to realize that system-
atic errors or systematic differences between labora-
tories can be constant or proportional. us 
A distinction between these two types can readily 
be made in a graph where the axes are graduated in 
UREA - mmol/1 
= 
22.76 +2SD r -- -- -- --
I I 
I I 20J3 M I I 
I § I E 
18.70 -250 A J 
L 
~2SD M +2SD 
4.35 4.84 5.33 serum 1 
FIG. 2. Youden-Tonks graph for urea (Second Eurotransp!ant 
Clin Chern Survey). Laboratories A- F reported to standardize in 
the nonnal range only. 
93 
VoL 67 o No. l QUALITY CONTROL IN CLINICAL CHEMISTRY 
units of measurement instead of SD. For example, 
in Figures 4 and 5 results for an N level control 
sample are plotted on the abscissa and results for 
an AN control sample on the ordinate. If only pro~ 
portional systematic errors are involved (Fig. 4), 
increasing with increasing concentrations of the con-
stituent, values for N and AN control samples will 
be higher or lower than the respective target values 
by differing amounts proportional to concentration. 
The target area, defined by M ± 2 SD, will be an 
upright rectangle, the slope of the diagonal line will 
be given by 
M high control sample SD high control sample 
M low control sample or SD low control sample ' 
and the diagonal line will pass through zero. If constant 
systematic errors are involved, values· for both 
samples will be 'higher Or lower than the respective 
mean value by the same amount, irrespective of the 
concentration of the constituent (Fig. 5). The diagonal 
line of the square target area is a 45-degree line. 
Many nonspecific procedures, for example for glucose, 
creatinine or cholesterol, measure a fixed amount of 
background, as compared with specific procedures for 
these constituents. 
In a group of laboratories constant and proportional 
errors will occur. In the Youden- Tonks graph the 
target area and the position of the diagonal line are 
CHOlESTEROL - mmol/1 
G 
4.14 +250 
3.BO M 
3.46 -2SO 
I -250 M +2SD 
L - --+-------1!-------1---
3.78 4.12 4.46 "'rum I 
FIG. 3. Youden-Tonks graph for cholesterol (MSPQCP-1974 
pools). Laboratory G shows systematically high values for serum II. 
probably due to bilirubin interference. 
mmol/1 
~ 12 ,--;g I I 10 I ! I 
' 
I I 
I I 
I I 
4 
__ _j 
serum I \low) 
FTG. 4. Hypothetical two-sample plot, axes graduated in units 
of measurement, of a group of laboratories, showing proportional 
differences from the target value ( + ). 
mmol/1 
~ 12 
6 
10 [2J 5 ' 1 I 6 - _ _j 
4 
serum I How) 
FIG. 5. Hypothetical two-sample plot, axes graduated in units of 
measurement. of a group of laboratories. showing constant dif-
ferences from the target value ( + ). 
defined by M ± 2 SD, the SD being derived from the 
combined dat:... If the majority of laboratories show 
constant systematic differences from the target value, 
the coincidence point of a laboratory showing propor-
tional systematic error will be interpreted as being due 
to random error. 
An example is given in Figure 6. In the Youden-
Tonks graph for cholesterol (MSPQCP, 1975 pools), 
axes graduated in SD (Fig. 6A), laboratories H, J, and 
K show random errors according to conventional 
interpretation. From the graph in units of measure-
ment (Fig. 6B), it can be concluded that most labora-
tories show proportional systematic errors, while 
laboratories H. J, and K show a constant systematic 
difference from the mean of all laboratories; this 
finding correlates with the fact that these laboratories 
use a method with extraction. 
A similar situation is illustrated in Figure 7. In a two~ 
sample plot graduated in units of measurement for 
creatinine (MSPQCP, 1974 pools) the average results 
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CHOLESTEROL- rnmol(l 
' ' CHOLESTEROL - mmol/1 
+2SD I I 
'·' I I 
7.28 +2$0 I -- -- -- --
5.5 I 
M I 
'·' 
M 
50 I 
"J I 
' "J " 
' L 5.20 -250 -- -- -- -- _j -2$0 _j 
5.0 
I 
-250 M +2SD -250 M +250 L_ L 
3.86 4.34 4.82 >erurn I 
'·' " 
5.0 serum I 
FIG. 6. A (hj{). Youden-Tonks graph for cholesterol {MSPQCP-1975 pools). Axes are graduated in SD. Laboratories H, J and K 
(employing a method with extraction) show random errors according to conventional interpretation. 
B {rh;lu), two-sample plot for cholesterol. axes graduated in units of measurement. From this graph it can readily be concluded that 
laboratories H, J and K show constant systematic differences from the mean of all laboratories. while the majority of laboratorie<; show 
proportional systematic errors. 
(capitals) and daily values (small print) for laboratories 
X and Y are entered. R is the mean value for four 
reference laboratories.* The mean value for laboratory 
X is situated on the line with a slope 
ref. value serum II 
ref. value serum I 
through the reference value, suggesting a proportional 
systematic difference from the reference value. The 
difference was negligible after renewal of the standard. 
Laboratory Y appears to have a constant systematic 
error with respect to the reference value, although the 
dispersion of the daily results indicates large random 
variability. (It is interesting that additional information 
can be derived from the "dot-cloud" of daily results. 
~!t is interesting that for the 1974 pools of the MSPQCP. for 
all components where the concentration in the AN serum is more 
than 2.5 times that in the N control serum (e.g .. urea. glucose. 
creatinine). the reference laboratories" mean value for the AN serum 
is significantly higher than the mean for all laboratories. Nonlinearity 
may be a common error. causing a low value for the mean of all 
laboratories for the AN serum. 
The dispersion of laboratory X's plotted points shows 
a trend, and we conclude that there is a small pro-
portional systematic error in the laboratory due to, 
e.g., instability of the standard. Similarly, we can 
expect in a procedure with baseline problems a dot-
cloud along a 45-degree line). 
Conclusion 
We summarize this discussion of the interpretation 
of the Youden- Tonks graph as follows: in the present 
situation in a single external quality control survey, 
where control materials contain constituents in dif-
ferent concentrations, a point deviating from the 
diagonal line can be attributable to (1) random intra-
laboratory variability, (2) systematic error in the labo-
ratory, (3) constant systematic error if proportional 
systematic errors prevail in the group under study, or 
(4) proportional systematic errors if constant syste-
matic errors prevail. 
A point on the diagonal line indicates only that, on 
this occasion, the laboratory shows the same type of 
systematic differences from the target value as the 
majority of laboratories. 
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Proposal 
More information can be derived from a two-sample 
plot in external quality control programs if the program 
is designed with the possibility of collecting multiple 
results for the .same sets of control materials. 
Plotted in a two-sample plot graduated in units of 
measurement, the position of the mean value will give 
information about persistent proportional or constant 
systematic differences from the target value. By in-
spection of the "dot cloud" of accumulated results, 
the presence of recurring systematic errors in the 
laboratory affecting day-to-day variability, such as 
instability of the standard or baseline problems, can 
be detected. 
A format for reporting in external quality control 
programs based on these premises has been in use 
for more than a year in a group of six laboratories 
in the Netherlands using the· quality control serum 
pools of the MSPQCP as a primary or secondary 
control. The form (Fig. 8) gives the following 
information: 
I. A table stating the laboratory's monthly mean, 
SD, and coefficient of variation (CV). SD and CV are 
calculated as soon as a total of 20 results is received. 
2. A graphic display of daily results (arabic numerals) 
CREATININE- mmol(l 
,-
' M + ' 
I 
-2SO M 
L- --'-,-~-L,----',-
"" 
190 ,..rvm I 
FIG. 7. Two-sample plot for creatinine, axes graduated in units 
of measurement. X "" mean value, laboratory X; x = daily results, 
laboratory X; Y = mean value, laboratory Y; y =daily results, 
laboratory Y. For explanation see text. 
II 
" 
22..0 
1.1.5' 
2./.0 
2.0.5 
MASSACHUSETTS SOCIETY OF PATHOLOGISTS 
QUALITY CONTROL PROGRAM 
lob. nr. 
"""'""'""' month 
oorum X-1 
!!."'9-" 
"' 
"' M '""""'ofolllobo; 
-2-• 2 SO ITmTn oil lobo; 
R , "'"""of rof. lobo. 
" 
"10" daTiy ,.,uln yo<" lob. Octob.r 
"X" mo"" your lob. Octob.i ole. 
J""""'" 11"1 IITit'" 
I 
6.< Y." 8.0 
FlG. 8. Example of the suggested form for reporting in external 
quality control programs. Two lines may be drawn through the 
tar~et value. one M a slooe of I, the other at a slope of 
target value serum II 
target value serum I 
and monthly means (roman numerals) in a two-sample 
plot with axes graduated in units of measurement. 
Discussion 
It has been demonstrated that the Youden~ Tonks 
plot, when used to picture results surveyed, may fail 
to distinguish between systematic and random errors 
when control materials in different concentrations are 
used. One of the consequences is that numerical data 
expressing the difference of an individual result from 
the target value as a proportion of the SD observed 
for all laboratories (SD interval,9 variance index16) give 
an evaluation of laboratory performance that is not 
really useful. 
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The existence of systematic errors causing plotted 
points to deviate from the diagonal line in the Youden-
Tonks graph has been proven by the fact that the 
laboratory in question consistently reported the same 
deviating result. In the quotation of Skendzel and 
Youden (see introduction) the word "consistent" is 
mentioned twice in correlation with systematic error. 
It should be realized that single testing of two 
samples covers within-run variability or consistency; 
multiple testing is needed to check the influence of 
day-to-day variability. This is particularly important in 
view of recent reportSJ.5 that intra-laboratory varia-
bility can be considerable and may obscure systematic 
differences between laboratories. 
The proposed two-sample plot has been helpful in 
identification of sources of error in the laboratory and 
in improving day-to-day precision and compatibility 
with the target value. Intra-laboratory quality control 
with a two-sample plot (Twin-plot®) has been de-
scribed by Griffin and Greeban. 7 In the Twin-plot, 
however, the center point of the graph is the labora-
tory's own mean value instead of a target value, which 
eliminates the possibility of simultaneous external 
quality control. 
As regards the interpretation of the proposed two-
sample plot, the following remarks are in order: 
1. Before a conclusion as to proportional or constant 
systematic differences from the target value can be 
reached, it is necessary to consider the possibility 
of systematic errors in the laboratory such as, for 
example, nonlinearity. If, in addition to the control 
materials in the different concentrations, a 1: I mixture 
of the two is tested, it will be possible to determine 
whether the system shows constant or proportional 
systematic differences over a range of concentrations 
(cf. operational line, Grannis6). The quality control 
serum value/absorbance standard graph has also been 
suggested2 for detection of this type of systematic 
error in the laboratory. 
2. For a number of constituents, the difference 
between N and AN levels is relatively small. Here, 
a difference between proportional and constant sys-
tematic differences will be difficult to detect. As an 
example, however, we would like to mention how a 
differentiation can be made for potassium, if the N 
ll!vel target is 4.0 mmol/1 and the target value for the 
AN level 6.0 mmol/1. A constant systematic difference 
of 0.4 mmol/l would bring the values up to 4.4 and 
6.4 mmol/1, respectively; a proportional systematic 
difference of 10% would bring them to 4.4 and 6.6 
mmol/1. If I SD often determinations is 0.09 (1.5%) at 
the 6 mmol/l level, the difference (6.6 - 6.4 = 0.2 
mmol/1) will be significant at p < 0.01, the Student's 
t value being 5.0. If I SD is 0.18 mmol/1 (3%), 
t will be 2.5 and the distinction between proportional 
and constant differences with the target value can still 
be made with a p between 0.05 and 0.02. 
The graphic display of survey results was proposed 
by Skendzel and Youden for easy visual interpreta-
tion.10 Presently, there is a tendency towards a 
large output of numerical data in quality control 
programs. 9 The suggested individual cumulative two-
sample plot in units of measurement is suited for both 
manual and computerized data handling, and will 
provide participants with much useful information 
from visual inspection of the graph. 
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ADDENDUM II 
Potossium 
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Figure 4-3: 
Histograms of action levels given by clinicians per hospital (numbered 1 through 12). The labora~ 
tories' upper and lower limits of normal are indicated by arrows. 
At the bottom of each figure histograms are given of accumulated data. 
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Total Protein 
20 30 50 60 70 so ,.~ lob. nr. D ~ • k 2 2 LJ u 
• L 
• .1. 4 I+ 'nJ 5 ~ r-' 
-=v 
6 LJ 
LJ LJ u j ~ LJ ~ ~ D:DE 7 
= 
a 
9 
b oLJ 10 ou D 'D 
11 
6o LJ~LJLJ 12 N 
IE ~ I ~ : IZil 
"" 
1'221 R~~ ~ 
20 30 40 50 60 70 so 90 gr/1 
Figure 4-3 cont. 
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